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ABSTRACT 
PARTIAL vs. FULL SUPPORT OF THE HEART WITH A CONTINUOUS-FLOW 
LEFT VENTICULAR ASSIST DEVICE: IMPLICATIONS FOR 
MYOCARDIAL RECOVERY 
Carlo Renato G Bartoli 
April 14,2011 
INTRODUCTION: Heart failure is a major and growing public health concern. Although 
heart failure has been considered an inexorable and progressive disorder, emerging 
evidence suggests that some patients may have reversible left ventricular dysfunction. 
Indeed, recent reports have documented the potential for myocardial recovery in humans in 
response to prolonged mechanical circulatory support with a left ventricular assist device 
(LVAD). However, myocardial recovery remains uncommon, and a strategy of unloading 
the failing left ventricle with a continuous-flow (non-pulsatile) LV AD has not been 
specifically developed to promote favorable myocardial remodeling. As a preliminary 
investigation, we developed a bovine model of chronic, ischemic heart failure and 
quantified the effects of different levels of support with a continuous-flow LV AD on 
myocardial mechanoenergetics. 
METHODS: Normal cows (n=8) and cows with chronic, ischemic heart failure (n=9) were 
studied. To induce heart failure, 90 fAm micro spheres were percutaneously injected into the 
v 
left main coronary artery. Heart failure developed over 60 days. In an acute surgery, a 
continuous-flow LV AD was implanted and operated at Low Partial Support (~1.5 Llmin 
support, aortic valve opening every beat), High Partial Support (~3 Llmin support, aortic 
valve opening every beat) and Full Support (~5 Llmin, aortic valve maintained closed, left 
ventricle maximally unloaded). Cardiac and systemic arterial hemodynamics were 
measured with flow probes and pressure catheters. Myocardial blood flow was mapped 
with 15 !lm fluorescent-labeled microspheres. After termination, molecular and 
histological markers of heart failure were quantified. 
RESUL TS: In normal animals, increasing levels of non-pulsatile support deranged the 
profile of cardiac and arterial hemodynamics. As cardiac workload decreased, myocardial 
vascular resistance increased, and myocardial blood flow decreased. The ratio between 
blood supply and demand did not change and indicated appropriate coronary autoregulation 
and the presence of an intact coronary reserve. Animals with chronic, ischemic heart 
failure exhibited hallmark signs of severe left ventricular systolic dysfunction that included 
a 50% reduction in ejection fraction, left ventricular dilatation, decreased cardiac output 
and arterial pressures, decreased end-organ blood flow, severe myocardial fibrosis, 
myocyte hypertrophy, and increased myocardial apoptosis. In animals with chronic heart 
failure, increasing levels of non-pulsatile support similarly deranged the profile of cardiac 
and arterial hemodynamics. As cardiac workload decreased, myocardial vascular 
resistance increased. However myocardial blood flow did not change and indicated a lack 
of a coronary reserve. Importantly, during full but not partial support, the ratio between 
blood supply and demand improved significantly to levels observed in normal control 
animals. 
vi 
CONCLUSIONS: After the implantation of an LVAD, full but not partial support of the 
failing left ventricle with an LV AD normalizes the myocardial blood supply/demand 
relationship. In the immediate postoperative period, the left ventricle should be completely 
unloaded. Chronic studies are necessary to determine whether a transition to partial 
support may prevent myocardial atrophy and fibrosis that is seen with prolonged full 
support. Our bovine model of chronic, ischemic heart failure is appropriate for such a 
study. 
vii 
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Adult patients with advanced heart failure that is refractory to pharmacological and 
electrical resynchronization therapies have a limited prognosis. For select patients, heart 
transplantation offers the best opportunity for long-term survival. However, the number 
of available donor hearts (~3,500 annually worldwide) are inadequate to meet the needs 
of more than 30,000 patients listed for heart transplantation worldwide each year!. As a 
result, cardiac transplant waiting lists have the highest mortality rate (30%) of any of the 
solid organ waiting lists2• 
If a patient decompensates while on a transplant waiting list and he or she is not granted 
high-urgency status, or if the rate of decompensation is rapid, limited options exist. If a 
patient does receive a donor heart, chronic rejection and sequelae of long-term 
immunosupression limit post-transplant survival to 55% at 10 years3. Furthermore, many 
patients are not considered for transplantation due to age, comorbidities, or even 
inadequate insurance coverage. As a result, many patients are being considered for 
therapy with a permanent, left ventricular assist device (L VAD). Indeed, over the past 
decade mechanical circulatory support therapies have emerged as a standard, long-term 
1 
therapy for adult patients with advanced, intractable heart failure as a bridge to cardiac 
transplantation4, a destination therapy4, or a bridge to myocardial recovery5-9. 
The recent, widespread success of mechanical circulatory support has ushered in a new 
era of cardiovascular medicine in which multiple implantable options exist to treat 
advanced heart failure. Currently, more than 20 novel cardiac assist devices are under 
development or in clinical trials with nearly a dozen new systems poised to begin clinical 
trials during the first half of the decade 1o-25. Each device entails unique surgical and 
physiological considerations and offers benefits and drawbacks for the patient and the 
physician. For example, currently available LVADs require extensive, invasive surgery 
such as sternotomy or thoracotomy. However, these "full-support" devices are able to 
salvage end-stage heart failure patients by replacing cardiac function and reinstating an 
adequate circulation. Consequently, full-support devices are reserved as a final treatment 
option only for patients with life-threatening heart failure. As such, full-support L VADs 
have not been specifically designed to recover a sick heart, and physicians may be 
reluctant to refer less-sick patients for an invasive therapy. 
In order to expand the role of mechanical circulatory support for the treatment of less-
severe stages of heart failure, investigators and industry partners are miniaturizing 
LVADs for less-invasive and earlier therapy. Small devices that are designed to provide 
moderate or "partial-support" in heart failure patients with less advanced disease may be 
employed before the onset of irreversible myocardial damage and end-organ dysfunction. 
It has been speculated that partial unloading of the failing left ventricle will interrupt the 
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progressive hemodynamic deterioration observed in 'heart failure 14 as well as increase 
functional capacity and improve quality of life. Partial support initiated in patients with 
less severe myocardial damage may increase the rate of myocardial recovery. Although 
there is limited data to support these hypotheses, initial clinical results with partial-
. . 14 24 26 27 
support deVIces are encouragmg . . . . 
As mechanical circulatory support gains prevalence in the clinical management of 
cardiovascular disease, it is increasingly important to characterize the physiological 
response to different devices and mechanical strategies to support the failing heart. Each 
new L V AD system unloads the left ventricle by a distinctive mechanism. Pulsatile 
devices mimic pulsatile heart function, whereas continuous-flow devices continuously 
(and non-physiologically) unload the heart. Full-support devices replace intrinsic cardiac 
function, whereas partial-support devices augment native hemodynamics. The diversity 
of strategies to support the failing circulation, the anticipated arrival of numerous novel 
devices, and the increasing prevalence of patients undergoing long-term mechanical 
circulatory support raise important basic physiological and clinical questions. 
F or example, what is the optimal strategy of support to promote myocardial recovery 
with an LV AD? Mounting evidence suggests that full support of the failing left ventricle 
with an LV AD can reverse pathologic myocardial remodeling and permit LV AD 
explantation in select patients5-9. Yet, strategies to promote myocardial recovery with a 
full-support LV AD have demonstrated limited success. In fact, the current strategy of 
prolonged full support of patients in end-stage heart failure with irreversible myocardial 
3 
damage may actually be detrimental to the cardiovascular system. As the level of 
continuous unloading increases, the native workload of the heart decreases28 . During full 
support, cardiac workload is nearly eliminated because native cardiac function is no 
longer needed for adequate circulation. As a result, myocyte atrophy29-31 and ventricular 
stiffening31,32 may occur and preclude myocardial recovery. Therefore, an understanding 
of effects of mechanical unloading of the heart on myocardial mechanoenergetics is 
needed in order to develop better support strategies to promote myocardial recovery. 
It is generally recognized that varying the level of support with an LV AD affects 
myocardial workload and coronary blood flow33 . Yet this relationship has not been well 
characterized and the implications of altered workload and coronary blood flow for 
myocardial recovery are unclear. As a starting point, characterization of the blood 
supply/demand relationship during LVAD support may answer fundamental questions 
necessary to begin to develop a protocol to promote myocardial recovery with a 
continuous-flow LVAD. The purpose of this dissertation project was to examine cardiac 
and arterial hemodynamics, coronary blood flow, and myocardial workload during 
varying levels of support with a continuous-flow LVAD28. To this end, a bovine model 
of chronic heart failure was developed. Continuous-flow LVADs were implanted in 
normal calves and calves with chronic, ischemic heart failure. During partial and full 
support with a continuous-flow LVAD, hemodynamics and myocardial blood flow were 
measured. The data presented within this dissertation document four important findings: 
4 
I) Left main coronary artery microembolization induced chronic, ischemic 
heart failure in calves. A stable and reproducible large-animal model of 
chronic heart failure is possible with many phenotypic similarities to clinical 
heart failure. 
2) In normal animals and animals with chronic heart failure, full but not partial 
support with a continuous-flow LV AD deranged the physiological profile of 
pulsatile cardiac and arterial hemodynamics. 
3) In normal animals, neither full nor partial support with a continuous-flow 
LV AD affected the myocardial blood supply/demand relationship. However, 
in animals with chronic heart failure, full but not partial support normalized 
the myocardial blood supply/demand relationship. 
4) Divergent results were observed between normal animals and animals with 
chronic heart failure. Normal animals do not reproduce the complex 
pathophysiological presentation of chronic heart failure and are not ideal for 
validation and proper translation of mechanical circulatory support 
strategies into clinical practice. 
The major finding of this study is that in the immediate postoperative period after the 
implantation of an LV AD, complete unloading of the failing left ventricle will rebalance 
the myocardial blood supply/demand relationship. However, full support with a 
5 
continuous-flow LV AD dramatically changes cardiac and systemic arterial 
hemodynamics and may have long-term consequences. Therefore, chronic studies are 
necessary to determine whether a transition to partial support may alleviate or prevent 
myocardial atrophy and fibrosis that is seen with prolonged full support. Our bovine 
model of chronic, ischemic heart failure is appropriate for such a study. 
6 
CHAPTER II 
BACKGROUND AND LITERATURE REVIEW 
I. Pulsatility during Mechanical Circulatory Support 
Over the past two decades, full-support LV ADs have evolved into a standard therapy for 
patients with end-stage heart failure. In 2002, the milestone Randomized Evaluation of 
Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial 
demonstrated clinical success with pulsatile L VADs as a long-term therapy for end-stage 
heart failure patients34 . Subsequently, the United States Food and Drug Administration 
(FDA) approved use of the first -generation, pulsatile HeartMate XVE (Figure 1, Left) as 
a destination therapy in patients ineligible for cardiac transplantation35 . 
More recently, pulsatile LV ADs, which mimic pulsatile cardiac function, have been 
replaced by rotary blood pumps, which continuously (and non-physiologically) unload 
the left ventricle. In 2008, the FDA approved use of the HeartMate II (Figure 1, Right) 
continuous-flow LVAD in patients for bridge-to-transplant therapl6. Such next-
generation, full-suPPOli rotary pumps are smaller, more reliable, more energy efficient, 
and less surgically traumatic to implant. Notably, superior clinical outcomes have been 
7 
established with next-generation continuous-flow devices37. Yet continuous-flow 
L V ADs do not generate normal pulsatility (Figure 2)28. As a result, a new population of 
"pulseless" patients undergoing long-term LV AD support has emerged. 
Pulsatile-Flow LVAD Continuous-Flow LVAD 
~~4-XVE 
LVAD 
Skin Vent Adapter 
LIM & Vent Flltor 
XVE System 
Controlle, 
Figure 1, Left: A pulsatile HeartMate XVE is shown. First generation pulsatile devices 
mimic native cardiac function. However, these devices are large, difficult to implant, and 
less reliable for long-term therapy. Right: A continuous-flow (non-pulsatile) HeartMate 
II is shown. Second generation continuous-flow devices are smaller, easier to implant, 
and operate with excellent durability for prolonged LVAD therapy. However, the non-
pulsatile mechanism dramatically alters the circulation of blood. 
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Figure 2, Left: Full support with a pulsatile LV AD demonstrates a normal pulsatile 
arterial pressure. As blood volume is removed from the left ventricle in a phasic manner, 
an arterial pulse is generated. Additionally, sufficient preload permits the left ventricle to 
eject through the aortic valve, which preserves a normal pulsatile circulation. Right: In 
contrast, full support with a continuous-flow LV AD demonstrates a nearly flat arterial 
pressure. As blood volume is continuously removed from the left ventricle into the aorta, 
insufficient preload prevents ejection of blood through the aortic valve. As a result, left 
ventricular pressure never exceeds aortic pressure, the aortic valve remains chronically 
closed, and the systemic circulation is non-pulsatile. AoP, aortic pressure; LVP, left 
ventricular pressure 
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In this patient population, investigators have raised concerns about the effect of chronic, 
non-pulsatile blood flow on myocardial and end-organ perfusion, cardiovascular 
h· d I . 38 arc Itecture, an ong-term patient outcomes . 
Pulsatility and mechanical stretch of cardiac myocytes, endothelial cells, and vascular 
smooth muscle cells are fundamental to cardiovascular homeostasis. On day 26 of 
human embryogenesis, the immature fetal heart begins to beat and pump blood through a 
rudimentary vascular system39. From this day forward until the last day of life, cardiac 
contraction, stroke volume ejection, and cardiac relaxation with one-way valves expose 
every cardiovascular cell (and most cells in the body) to rhythmic mechanical forces that 
mediate intracellular and extracellular events. Seemingly, pulsatility is a vital component 
of normal mammalian physiology. 
Indeed, numerous investigators have demonstrated the superiority of pulsatile blood flow 
over non-pulsatile flow during short-term and long-term mechanical circulatory support 
in experimental models as well as in adult and pediatric patients40-52 . However, despite 
the evidence in favor of pulsatile perfusion techniques, a debate still exists as to which 
mode of circulatory support is better. A separate set of investigators have reported no 
difference between continuous and pulsatile perfusion modes53-59• 
Nevertheless, continuous-flow LVADs constitute the current clinical gold standard for 
prolonged mechanical circulatory support37• Yet the effect of continuous support of the 
left ventricle and redU(~ed pulsatility on cardiac workload, coronary blood flow, and 
9 
regional myocardial perfusion remain largely uncharacterized. During heart failure, the 
supply/demand ratio of available oxygen in blood to myocyte workload becomes 
unbalanced60. Likely, appropriate support with an LV AD may rebalance this 
relationship, which may have important implications as the initial step toward myocardial 
recovery. 
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II. Partial vs. Full Mechanical Unloading of the Failing Left Ventricle 
If a patient awaiting a cardiac transplant decompensates and an appropriate organ is not 
available, a full-support LV AD may be the only option for survival. Yet many heart 
failure patients are not ill enough or have contraindications to placement of a full-support 
LV AD. In these patients, the notion of combining the benefits of partial support with a 
minimally invasive and short operation without cardiopulmonary bypass may be feasible. 
A recent National Heart, Lung, and Blood Institute (NHLBI) mission statement included 
the pursuit of long-term hemodynamic support with minimally invasive surgery to 
provide moderate levels of mechanical assistance earlier in the progression of heart 
failure (NHLBI, Clinical Use of Ventricular Assist Devices Working Group, March 27-
28,2008 Crystal City, VA)61. The long-term benefits of chronic, partial support are 
unknown but may soon be partially characterized by ongoing clinical trials14. Significant 
clinical benefits have been predicted62 that may decrease the number of patients that 
require a heart transplant. 
For example, a large gap in available therapies exists for patients in NYHA class III heart 
failure that have not responded to biventricular pacing. If these patients are transplant 
ineligible or have not met hemodynamic and clinical criteria to justify risks and 
comorbidities of sternotomy and a full-support LV AD, limited options exist. In these 
patients, partial supp0l1 with a less-invasive device is an attractive option. If partial 
support is administered early enough, favorable reverse myocardial remodeling may 
11 
restore sufficient native cardiac function and permit explantation of the device7. This 
hypothesis has not been rigorously tested but is conceptually appealing. 
Indeed, in rare instances, full support with an LV AD has resulted in myocardial 
recovery5-9. In these patients, functional recovery has accompanied favorable changes at 
the molecular and histological levels 7,63,64. Yet, strategies to promote reverse myocardial 
remodeling with a full-support LV AD have demonstrated limited success and myocardial 
recovery remains uncommon. As it turns out, prolonged full support of the left ventricle 
with a continuous-flow LVAD may produce numerous unfavorable results. For example, 
as the level of full-support increases, variation in end-systolic and end-diastolic volumes 
diminish and eliminate the native workload of the heart28. Myocyte atrophy29,30 and 
ventricular stiffening32 may occur and produce a noncompliant ventricular chamber 
incapable of sustained, independent function. Simultaneously, complete volume 
unloading of the left ventricle decreases peak systolic pressures to the point where the 
aortic valve remains chronically closed. As a result, fused valve leaflets, acquired aortic 
stenosis, or total occlusive thrombosis of prosthetic aortic valves may occur65 . Excessive 
ventricular unloading with an LV AD may also result in suction events and ventricular 
collapse, which may trigger episodes of fatal ventricular tachyarrhythmias66, 67. 
Of additional concern, during therapy with a full-support LV AD, approximately 30% of 
patients develop right ventricular dysfunction68 with an associated mortality rate of 
43%69. During left heart failure, full support with an LV AD may abruptly increase 
systemic arterial flow, acutely overload the right ventricle, and cause right ventricular 
12 
failure. For these reasons, full support of the left ventricle with a continuous-flow L VAD 
may cause adverse consequences and limit myocardial recovery. 
Furthermore, patients in NYHA class III or early class IV heart failure with less-
advanced disease may not require full support with an LVAD. Accordingly, rather than 
completely unloading the failing heart, earlier and partial unloading may reduce but not 
eliminate native ventricular workload, preserve myocardial structure, and prevent 
myocyte atrophy and ventricular stiffening. By reducing ventricular workload and 
augmenting myocardial blood flow while still allowing the heart to fill and empty over a 
controlled range of ventricular volumes, partial support may be an effective strategy not 
only to augment hemodynamics but also to promote favorable myocardial remodeling in 
hearts with less disease. Importantly, patients with healthier hearts may have a higher 
likelihood of myocardial recovery62. 
With this strategy in mind, preclinical studies are necessary to determine effects of partial 
support on cardiovascular physiology. Therefore, the purpose ofthis dissertation project 
was to initiate in vivo, large-animal experiments to characterize the effect of full and 
partial support with a continuous-flow LV AD on systemic hemodynamics and the 
myocardial blood supply/demand relationship. Our findings have important clinical 
utility and may increase the public-health impact of mechanical circulatory support with 





Full-support devices constitute the current gold standard for the treatment of end-stage 
heart failure with an LVAD. Myocardial recovery with a continuous-flow LV AD is rare, 
and effective strategies to facilitate reverse myocardial remodeling have not been 
developed. The field of mechanical circulatory support is trending toward miniaturized 
L V ADs that can be implanted with minimally invasive surgery and that provide partial 
support for earlier therapy in healthier patients. The clinical utility of partial support is 
unknown. However, partial support of patients in earlier stages of heart failure may be a 
better strategy to promote myocardial recovery. 
II. Proposed Concepts 
Important hemodynamic differences exist between partial vs. full support of the 
cardiovascular system. The effect of continuous unloading of the left ventricle on cardiac 
and systemic hemodynamics, myocardial workload, and coronary blood flow is not well 
characterized. The effect of partial support with a continuous-flow LVAD on myocardial 
14 
mechanoenergetics is unknown, and the clinical role of partial support is yet to be 
defined. 
III. Experimental Design 
A series of experiments were designed to compare effects of partial vs. full support with a 
continuous-flow LV AD on cardiac and systemic hemodynamics, myocardial workload, 
and coronary blood flow. In normal animals without cardiovascular pathology, 
continuous-flow LVADs were implanted to determine effects of partial support in the 
normal cardiovascular system. In parallel, a model of chronic, ischemic heart failure was 
developed in calves. Experiments were repeated in the heart failure model to determine 
effects of partial support in the failing cardiovascular system. 
IV. Hypotheses and Specific Aims 
Hypothesis #1: In normal animals, increasing levels of support with a continuous-flow 
L V AD will alter the pulsatile cardiac and systemic arterial hemodynamic profile. 
Continuous mechanical unloading of the normal left ventricle will reduce left ventricular 
but not right ventricular workload and blood flow in a manner dependent on the degree of 
support. The left ventricular blood supply/demand relationship will not change. 
Aim #1: Characterize and Compare Hemodynamics and Myocardial Blood Flow during 
Partial and Full Unloading of the Normal Left Ventricle with a Continuous-Flow LV AD 
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The goals of this aim were to determine how support with a continuous-flow LV AD 
affected hemodynamics, cardiac workload, and myocardial blood flow in normal animals. 
Regional myocardial blood flow was related to cardiac and arterial hemodynamics. 
Hypothesis #2: Coronary microembolization will produce stable and reproducible 
chronic, ischemic heat1 failure in calves. 
Aim #2: Develop and Characterize a Bovine Model of Chronic Heart Failure 
The goals of this aim were to establish and characterize a stable and reproducible model 
of microembolization-induced chronic, ischemic heart failure. This model was used to 
test the hypothesis of Aim #3. 
Hypothesis #3: In animals with chronic heart failure, increasing levels of support with a 
continuous-flow L VAD will alter the pulsatile cardiac and systemic arterial 
hemodynamic profile. Continuous mechanical unloading of the failing left ventricle will 
reduce left ventricular but not right ventricular workload in a manner dependent on the 
degree of support. As a result, the unbalanced blood supply/demand relationship in the 
chronically hypoperfused myocardium will rebalance. 
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Aim #3: Characterize and Compare Hemodynamics and Myocardial Blood Flow during 
Partial and Full Unloading ofthe Failing Left Ventricle with a Continuous-Flow LV AD 
The goals of this aim were to determine how support with a continuous-flow LV AD 
affected hemodynamics, cardiac workload, and myocardial blood flow in animals with 




Aim #1: PARTIAL vs. FULL SUPPORT OF THE NORMAL LEFT VENTRICLE 
WITH A CONTINUOUS-FLOW LV AD 
I. Introduction 
Ongoing theoretical debate exists regarding the merits and limitations of partial vs. full 
circulatory support. With nearly 3,000 patients logged, the Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS) recently documented a 1-
year survival rate of 75% with full-support LVADs7o. Clearly, end-stage heart failure 
patients are benefiting from full-support L V ADs. Yet, better clinical outcomes are 
necessary before prolonged LVAD support is more widely accepted. For example, 
currently approved devices contain parts that wear down such as polymeric valves and 
diaphragms or mechanical contact bearings. To counter this limitation and increase 
device durability, third-generation, full-support devices include a bearingless, 
magnetically suspended impeller that does not wear over time or generate frictional 
heat J3 • As a result, many continuous-flow devices have been miniaturized. In patients 
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with moderate heart failure, earlier and minimally invasive partial support may preserve a 
near-normal pulsatile hemodynamic profile and reduce but not eliminate cardiac 
workload. 
Partial support with a minimally invasive surgical approach may also expand the 
potential patient population for LV AD therapy. As L V ADs are miniaturized, less-
invasive surgical approaches may increase acceptance by physicians who are more likely 
to refer patients for minimally invasive therapies7 ). Earlier intervention in less-sick 
patients should increase the public-health impact of mechanical circulatory support. 
In our laboratory, preliminary work in a mock circulatory system demonstrated marked 
differences in pulsatility, ventricular pressure-volume relationships, and coronary blood 
flow during partial vs. full support with a continuous-flow LVAD72 . However, in this in 
vitro study it was not possible to determine the effect of partial support on regional 
myocardial blood flow or the myocardial blood supply/demand relationship. A recent 
study in sheep demonstrated that increasing levels of support with a continuous-flow 
L V AD progressively decreased myocardial oxygen consumption, and coronary blood 
flow did not change33 • However, the authors did not normalize coronary blood flow to 
myocardial oxygen consumption, and the effect on the oxygen supply/demand ratio was 
not reported. FurthemlOre, this study was performed in normal animals without 
cardiovascular pathology. 
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In order to more rigorously characterize the effect of continuous unloading on the 
myocardial blood supply/demand relationship, Aim #1 was a first step in understanding 
the chronic consequences of full vs. partial support with a continuous-flow LV AD. The 
major goal was to examine acute responses in normal animals. Standard indices of 
cardiovascular performance and regional myocardial blood flow were measured during 
partial and full support of the normal left ventricle. The implication for reverse 
myocardial remodeling and myocardial recovery were considered. The results of this 
study will help to guide future investigation into acute and chronic effects of continuous-
flow mechanical circulatory support in large-animal models of chronic cardiac pathology. 
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II. Materials and Methods 
Animals 
Male Jersey and mixed-breed calves (n=8, 126±13 kg) were used. All animals received 
humane care and were handled in accordance with National Institutes of Health and 
University of Louisville animal care committee guidelines. Experimental procedures 
followed the University of Louisville Institutional Animal Care and Usage Committee 
approved protocol #08073. 
Anesthesia 
Animals were pre-anesthetized with Atropine (30 mg) and prepared for acute, non-sterile 
surgery. In the operating room, general anesthesia was administered with Isoflurane (3-
5%) and room air. The animal was placed on the operating table in right lateral 
recumbency. Tidal volume and respiratory rate were adjusted to maintain arterial oxygen 
saturation above 90%. Fluid-filled arterial and venous catheters were placed in the left 
carotid artery and jugular vein for blood sampling. A left thoracotomy was performed. 
Ribs #4 and #5 were resected. The pericardium was opened. The animal was 
anticoagulated with a single bolus of intravenous Heparin (100 units/kg). For the 
remainder of the procedure, the activated clotting time (ACT) was maintained above 250 
s with additional boluses of Heparin (1,000 to 2,000 units). 
Surgical Instrumentation 
A single-tip high-fidelity micromanometer catheter (Millar Instruments, Houston, TX) 
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was placed in the aorta and a dual pressure-volume conductance catheter (Millar 
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into 
the left ventricle for. simultaneous measurement of aortic, left atrial, and left ventricular 
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was 
placed around the pulmonary artery to measure cardiac output. In six animals, a silicone 
catheter (7-French, Access Technologies, Skokie, IL) was advanced in the left atrial 
appendage chamber for administration of 15 /lm fluorescent-labeled polystyrene 
micro spheres as described below. The depth and angle of catheter entry parallel to the 
surface of the left atrial appendage ensured that the catheter did not interfere with mitral 
valve function. 
L V AD Implantation 
A continuous-flow L VAD (HeartWare HV AD n=4, Thoratec HeartMate II n=2) was 
implanted with cardiopulmonary bypass. The outflow graft was anastomosed to the 
descending aorta. The left ventricular apex was cored and cannulated. The device and 
outflow graft were de-aired. A transit-time ultrasonic flow probe (Transonics, Ithaca, 
NY) was placed around the outflow graft to measure LV AD flow. 
Experimental Design 
In each animal, blood pressure and flow waveforms were recorded during Baseline 
(pump off, outflow graft clamped), Low Partial Support (~1.5 Llmin support, aortic valve 
opening every beat), High Partial Support (~3 Llmin support, aortic valve opening every 
beat), and Full Support (~5 Limin, aortic valve maintained closed, left ventricle 
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maximally unloaded). Baseline and support modes for each device were maintained for 
10 minutes each to achieve steady-state conditions prior to collection of 30 second data 
sets. During each condition, a single color of fluorescent-labeled micro spheres (5.25 
million micro spheres) was injected into the left atrial catheter. Simultaneously, a 
reference blood sample was withdrawn from the arterial line at a rate of 15 mllmin for 
100 seconds. 
Quantification of Microspheres and Regional Myocardial Blood Flow 
The microsphere technique enabled the precise measurement of regional blood flow in 
vascular beds of interest as follows. In the left ventricle, the micro spheres mixed with the 
blood and were ejected into the aorta to disseminate throughout the body to every organ 
according to the physiological distribution of blood flow during that experimental 
condition. As the micro spheres approached capillaries, they lodged within the smallest 
pre-capillary arterioles based on regional tissue blood flow patterns. With the quantity 
used, 15 !-lm spheres do not cause ischemia and did not induce pathology73. 
The aortic blood sample acted as a reference for later determination of flow in tissues of 
interest. The number of counted microspheres in the reference blood sample (known -
counted with flow cytometry) was compared to the number of micro spheres that lodged 
in pre-capillary arterioles and were counted in a tissue sample of interest (known -
counted with flow cytometry). The ratio between the two sphere counts was equal to the 
ratio between the calibrated rate of aortic withdrawal (known - 15 mllmin) and flow in 
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the tissue of interest (unknown) and provided accurate determinations of tissue specific 
flows in milliliters per minute per gram of tissue (ml/min/g)73, 74. 
At the completion of the study, while under anesthesia, euthanasia was performed with a 
fatal intravenous bolus injection of Beuthanasia-D Special (l mll5 kg). The heart was 
removed. One to two gram tissue sections from the left ventricular free wall, right 
ventricular free wall, interventricular septum, and left ventricular epicardium, mid-
myocardium, and endocardium were collected. Myocardial and reference blood samples 
were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion, counting of 
fluorescent microspheres with flow cytometry, and calculation of tissue specific blood 
flows in ml/min/g oftissue. 
Data Reduction 
All transducers were pre- and post-calibrated against known physical standards to ensure 
measurement accuracy. Calibration curves for the volume conductance catheter were 
constructed using static and dynamic tests pre- and post-experiment. Data were collected 
at 400 Hz, signal conditioned, and AID converted for digital analysis using our Good 
Laboratory Practices (GLP) compliant data acquisition system75. 
To determine hemodynamic performance during each support mode, pressure and flow 
waveforms were used to derive LV AD flow (LV ADF), heart rate (HR), left ventricular 
stroke volume (LV SV), pulmonary artery flow (P AF) as an index of cardiac output 
(CO), mean left atrial pressure (LAP), left ventricular end-diastolic pressure (L VPend 
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diastolic), left ventricular peak systolic pressure (LVPpeak systolic), ±dP/dt, aortic systolic 
blood pressure (AoPsystolic), aortic diastolic blood pressure (AOPdiastolic), mean aortic 
pressure (AoPmean), and aortic pulse pressure (AOPpulse). Rate-pressure product (HR x 
LVPpeak systolic), a standard index of cardiac metabolic demand76, was calculated. 
Myocardial vascular resistance was calculated as AoP mean/region-specific myocardial 
blood flow. Hemodynamic variables were calculated on a beat-to-beat basis for each 30 
second data set with the Hemodynamic Evaluation and Assessment Research Tool 
(HEART) program77 developed in Matlab (Version 6.5, MathWorks, Natick, MA). All 
analyzed beats in each data set (approximately 30 to 50 beats/30 second data set) were 
averaged to obtain a single representative mean value for each calculated variable. 
Statistics 
GraphPad, version 4.00 (Prism, La lolla, CA) was used to perform statistical analyses 
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed 
for each hemodynamic index, region of myocardial blood flow, and myocardial blood 
flow normalized to HR x L VP peak systolic to compare Baseline, Low Partial Support, High 
Partial Support, and Full Support modes within each animal. All analyses were two-
tailed, and a p-value<0.05 (95% confidence) was considered statistically significant. All 
data are presented as mean±standard error. 
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III. Results 
Table 1 demonstrated that in normal animals, as the level of support with a continuous-
flow LV AD increased, the cardiac and systemic arterial hemodynamic profile 
progressively changed. An increase in continuous support decreased HR and CO. 
Although the difference between Baseline and Full Support were not statistically 
different, the reductions were quantitatively large (HR, -16 bpm; CO, -0.9 Llmin). 
Left Ventricular Hemodynamics 
Left ventricular pressures demonstrated the most robust changes. The progressive 
increase in continuous support significantly decreased LAP (p=O. 01), L VP end diastolic 
(p<O.OO 1), and L VP peak systolic (p=0.05) with a dose-dependent response. These reductions 
were greatest and indicated maximum unloading during Full Support. Smaller reductions 
were observed during partial-support modes. Increasing levels of continuous support did 
not affect ±dP/dt. 
During Full Support, the variation between peak-systolic and end-diastolic pressures 
decreased to non-physiologically low values and resulted in chronic closure of the aortic 
valve. In this situation, the average LVPpeak systolic (77±11 mmHg) did not exceed the 
AoP diastolic (80±6 mmHg). As a result, the aortic valve remained closed, and HR x 
L VP peak systolic decreased significantly (p=0.05) to values that are not seen in normal 
animals. This finding indicated that unloading the heart with a continuous-flow LVAD 
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dramatically reduced myocardial metabolic demands and with a dose-dependent 
response. 
Arterial Hemodynamics 
Systemic arterial pressures demonstrated less robust changes. As continuous support 
increased, AoPmean and AOPsystolic did not change. However, during Full Support 
AoP diastolic trended toward an increase of nearly 10 mmHg (p=O.ll), and AoP pulse 
decreased significantly from 28±8 to 14±11 (p<O.OOOl). In contrast, during partial-
support modes, the arterial pulse pressure was not significantly changed from baseline. 
Myocardial Blood Supply/Demand Relationship 
In normal animals, continuous support of the left ventricle did not affect right ventricular 
myocardial vascular resistance or blood flow. However, in the left ventricle and 
interventricular septum, increasing levels of continuous support reduced the cardiac 
workload, increased myocardial vascular resistance (Table 2), and decreased regional left 
ventricular blood flow (Table 3) with a significant dose-dependent response. Changes in 
vascular resistance and blood flow in the epicardial region demonstrated that the coronary 
arteries and large coronary arterioles were participating in observed changes. 
To characterize the relationship between myocardial blood supply/demand, regional 
myocardial blood flow was normalized to HR x L VP peak systolic. Increasing levels of 
continuous support did not alter the ratio between left ventricular myocardial blood flow 




n=8 LVADF HR LV SV PAF LAP LVPonddlulollc LVP .... k.ystoIlc +dP/cIt -dP/cIt HR x LVPpuksystoHc AoP_ AoPsyatoIlc AoP_1c AoPpuI .. 
(L/min) (bpm) (ml) (L/mln) (mmHg) (mmHg) (mmHg) (mmHg/s) (mmHg/s) (bpm x mmHg) (mmHg) (mmHg) (mmHg) (mmHg) 
AN OVA p-value p<O.OOOl p=0.08 p=0.61 p=0.24 p=O.Ol p<O.OOl p=0.05 p=0.68 p=0.34 p=0.05 p=0.93 p=0.68 p=O.l1 p<O.OOOl 
Baseline 0.0:1:0.0 86:1:7 99:1:9 8.6:1:1.1 16:1:6 15:1:2 98:1:5 1,351:1:204 -1,609:1:160 8,627:1:1,085 84:1:5 100:1:5 71:1:5 28:1:3 
Low Partial Support 1.8:1:0.2* 72:1:5 108:1:17 7.9:1:1.3 15:1:5 16:1:2 96:1:6 1,517:1:295 -1,698:1:262 6,935:1:577 83:1:5 98:1:6 69:1:4 29:1:3 
High Partial Support 3.3:1:0.3*t 71:1:5 106:1: 13 7.5:1: 1.1 15:1:5 15:1:2 91:1:8 1,243:1:241 -1,420:1:175 6,463:1:753 83:1:5 95:1:5 73:1:4 22:1:3t 
Full Support 5.2:1:0.6*H 70:1:5 111:1:13 7.7:1:0.9 12:1:5* l1:1:2*t* 77:1:11 1,296:1:340 -1,299:1:349 5,568:1:971* 86:1:5 94:1:6 80:1:6 14:1:4*H 
Table 1: Hemodynamics during partial vs. full unloading of the normal left ventricle with a continuous-flow LV AD. LVADF, left 
ventricular assist device flow; HR, heart rate; LV SV, left ventricular stroke volume; P AF, pulmonary artery flow; LAP, left atrial 
pressure; L VP, left ventricular pressure; AoP, aortic pressure; *p<O.05, support mode vs. Baseline; tp<O.05, support mode vs. Low Partial 
Support; tp<O.05, support mode vs. High Partial Support 
ml/min/lOOglbpm·mmHg was established as the myocardial blood supply/demand 
relationship in normal animals. Figure 3 summarizes the gross physiological changes 
observed during continuous unloading of the normal left ventricle. 
n=6 RV LV Septum Epicardium Mid-Myocardium Endocardium 
(mmH!/mt/min/!1 (mmH!/m./mln/v} !mm!!!/ml/min/l!l (mm!!!/ml/mtn/!!! (mm!!!/ml/mtn/!l (mmH!/ml/min/gl 
AN OVA e-value e=0.47 e-0.07 e-0.04 e-0.07 e-0.02 e=0.08 
Baseline 138±28 120±22 114±20 138±30 106±20 133±21 
Low Partial Support 163±33 151±30 154±28 173±40 138±30 186±41 
High Partial Support 235±82 238±86 239±86 262±98 199±65 253±92 
Full Support 188±67 284±85 304±86* 328±108 277±75* 352±123 
Table 2: Regional myocardial vascular resistance during partial vs. full support ofthe 
normal left ventricle with a continuous-flow LVAD. RV, right ventricle; LV, left 
ventricle; *p<O.05, Full Support vs. Baseline 
n=6 RV LV Septum Epicardium Mid-Myocardium Endocardium 
{mllminlsl {mllminlsl {mllminlSll {mllminlSll {mllminlll {mllminlsl 
ANOVA Q-value Q=0.49 e-O.OS E-0.07 E-0.07 E=0.01 Q=O.l1 
Baseline 0.60±0.90 0.70±0.10 0.73±0.13 0.6S±0.13 0.80±0.12 0.61±0.08 
Low Partial Support 0.47±0.08 0.63±0.14 0.60±0.13 0.S8±0.14 0.69±0.14 0.S3±0.13 
High Partial Support 0.47±0.08 0.S2±0.13 0.S2±0.14 0.S1±0.14 0.S8±0.14 0.47±0.12 
Full Support 0.49±0.09 0.43±0.11* 0.38±0.09* 0.40±0.10 0.42±0.10* 0.3S±0.08 
Table 3: Regional myocardial blood flow during partial vs. full support of the normal 
left ventricle with a continuous-flow LV AD. RV, right ventricle; LV, left ventricle; 
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Table 4: Regional myocardial blood supply/demand relationship during partial vs. full 
support of the normal left ventricle with a continuous-flow LVAD. LV, left ventricle; 
HR, heart rate; L VP, left ventricular pressure 
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Myocardial Flow , 
Flow/Workload ... 0.0085 ml!min!lOOg!bpmommHg 
Figure 3: During support of the normal left ventricle with a continuous-flow LVAD, cardiac 
workload decreased, myocardial vascular resistance increased, and myocardial blood flow 
decreased. However, the relationship between blood supply and demand did not change and 




The study of partial vs. full support of the left ventricle with a continuous-flow LV AD 
was possible in normal animals. Specifically, in animals without cardiovascular 
pathology, 1) a systemic flow reserve was present, 2) full support with a continuous-flow 
L V AD deranged pulsatility whereas partial support preserved a more normal pulsatile 
profile, 3) as continuous support increased, left ventricular workload and blood flow 
decreased, likely as a result of appropriate coronary autoregulation and an intact coronary 
reserve. These results will help guide future acute and chronic studies in large-animal 
models of cardiac pathology to determine effects of partial vs. full support of the left 
ventricle with a continuous-flow L VAD. 
Systemic Effects 
In normal animals, a systemic flow reserve was present. As the level of support with a 
continuous-flow LV AD increased, HR and CO decreased in a dose-dependent manner. 
This finding in animals without chronic pathology was not unexpected. 
In chronic heart failure, a systemic flow reserve may be absent. Therefore, these results 
from normal animals likely cannot be generalized to animals with heart failure. 
It is possible that a lack of pulsatile blood flow drops systemic metabolism. To generate 
force, cardiac myocytes consume large quantities of oxygen78 • Similarly, because of 
pulsatile stretch and in order to maintain vascular tone, endothelial cells have the greatest 
oxidative metabolism of any cells in the body 79. As a result, during the generation and 
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regulation of arterial pulsatility, cardiac myocytes, endothelial cells, and vascular smooth 
muscle cells metabolize large quantities of oxygen. Therefore, the reduction of cardiac 
metabolic demands and arterial pulsatility with a continuous-flow L VAD is likely to drop 
total body oxygen requirements and therefore co. If this is the case, any level of support 
with a continuous-flow L VAD that reduces cardiac workload and arterial pulsatility will 
reduce total body oxygen consumption and benefit the heart failure condition. 
Effects on the Heart 
In the normal heart, full support of the left ventricle with a continuous-flow LVAD 
deranged the natural profile of pulsatile cardiac hemodynamics. As continuous support 
increased, the maximum pressure generated by the left ventricle dropped below the 
arterial diastolic pressure. Insufficient preload was available to eject through the aortic 
valve, which did not open. As a result, the workload of the heart was significantly 
reduced to values that are not normally observed in bovids. As workload decreased, 
myocardial vascular resistance increased, and myocardial blood flow decreased. The 
ratio between blood supply and demand did not change and indicated appropriate 
coronary autoregulation and the presence of an intact coronary reserve. Substantial 
changes in epicardial vascular resistance and blood flow further suggested that the 
coronaries were participating in this process and that coronary vasomotor function was 
normal. 
In chronic heart failure, a coronary flow reserve may be absent6o• Therefore, these results 
from normal animals likely cannot be generalized to animals with heart failure. 
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Effects on the Arterial System 
In normal arteries, full support ofthe normal left ventricle with a continuous-flow LVAD 
deranged the natural profile of pulsatile arterial hemodynamics. As continuous support 
increased, arterial diastolic pressure trended upwards, and AoP pulse was reduced by half. 
In contrast, partial support with a continuous-flow LV AD allowed the aortic valve to 
open on every beat. A normal profile of cardiac and systemic arterial hemodynamics 
with a near-normal pulse pressure was preserved. 
Potential Mechanism for Unfavorable Histological Changes during Prolonged LV AD 
Support 
Our findings suggest mechanisms by which diminished pulsatility may induce 
histological changes within the cardiovascular system during prolonged support with a 
continuous-flow LV AD. When cells in the heart and vasculature are exposed to 
chronically deranged mechanical forces such as during hypertension, pathological 
remodeling may occur. For example, chronic hypertension is well documented to induce 
concentric myocardial hypertrophy in the heart as well as tunica medial thickening and 
alterations of the collagen/elastin ratio in conduit arteries8o• During isolated systolic 
hypertension, pulse pressures are known to exceed 80 to 100 mmHg and affect cardiac 
and arterial tissues. Even the acute blood pressure elevations that are observed in 
malignant hypertension may induce acute pathological vascular remodeling that include 
hyperplastic arteriolosclerosis and fibrinoid necrosis. 
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During continuous unloading of the cardiovascular system, hemodynamics were similarly 
deranged but in the opposite direction of hypertension. Full Support reduced the peak 
left ventricular systolic pressure to a value below the diastolic arterial blood pressure, 
prevented the aortic valve from opening, and reduced the pulse pressure. As a result, 
myocardial metabolic demands decreased to values that are not encountered in bovids. 
Moderate reductions in metabolic demands are likely important, especially if the goal of 
treatment is myocardial recovery. However, the optimal reduction in cardiac metabolism 
which allows the heart to rest while maintaining a partial workload has not been 
established, and excessive myocardial unloading in which the heart performs too little 
workload may induce myocardial atrophy29, 30 and fibrosis3 !, 32. As a result, it is likely 
that the lack of adequate myocardial and arterial stretch during full-support in 
continuous-flow LV AD patients may induce architectural changes in cardiovascular 
tissues that have long-term consequences, especially ifthe goal is myocardial recovery. 
By maintaining pulsatility and a reduced cardiac workload, partial support may attenuate 
these effects. 
In summary, partial support with a continuous-flow LV AD is feasible and may preserve a 
more normal cardiac and systemic arterial hemodynamic profile. Effects of partial 
support during heart failure are unlikely to be the same as in normal animals, and the 
clinical utility of partial support remains to be determined. 
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CHAPTER V 
Aim #2: DEVELOPMENT OF A BOVINE MODEL OF CHRONIC, 
ISCHEMIC HEART FAILURE 
I. Introduction 
The development of a stable and reproducible model of chronic heart failure with a low 
mortality rate is critical for successful translational research on the clinical treatment of 
heart failure. A large-animal model which closely mimics the human cardiovascular 
condition (bovine or ovine )81 is necessary for the preclinical testing of implantable 
devices as well as to examine (patho )physiological processes associated with mechanical 
circulatory support. In terms of anatomical size of the thorax and physiological function 
of the cardiovascular system, normal calves have been used for decades as the industry 
standard to test safety, performance, and reliability of LV AD systems-phylogenetically 
lower species are too small to accommodate implantable cardiac devices. Yet large-
animal models of chronic cardiac pathology have only been used to a limited extent to 
investigate mechanical circulatory support82-84 and adjunct therapies85 and have not been 
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used to determine efficacy or to compare the physiological benefits of different strategies 
of mechanical circulatory support. As a result, mechanisms of reverse myocardial 
remodeling, myocardial recovery, and pathophysiological responses to mechanical 
circulatory support such as ischemic and hemorrhagic stroke86, acquired von Willebrand 
disease87, 88, diastolic hypertension57, 58, and gastrointestinal arteriovenous malformations 
and bleeding89 are largely uncharacterized. 
Rapid-pacing, volume overload, pressure overload, coronary ligation, microembolization, 
and cardiotoxic drugs have been used to induce chronic heart failure in multiple species90• 
Additionally, spontaneous genetic cardiomyopathy exists in Holstein-Fresian cattle91 , 92. 
Yet, models of chronic, experimental bovine heart failure83, 93 are infrequent in the 
literature. 
Ischemic cardiomyopathy is the most prevalent etiology of heart failure in human patients 
and currently affects more than 3 million people in the United States alone94• As such, 
large-animal models of chronic, ischemic heart failure are necessary to translate basic 
discoveries into clinical utility. Coronary microembolization models of ischemic heart 
failure have been developed and validated in sheep95-99 and in dogsIOo. In these studies, 
50 to 120 11m spheres injected into the coronary arteries lodged within pre-capillary 
arterioles, produced myocardial ischemia distal to the lodged spheres, and induced a 
severe, global left ventricular dysfunction. Over the course of days to weeks, animals 
developed a stable and reproducible state of left ventricular failure. 
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Similarly, a bovine model of ischemic heart failure is urgently needed for preclinical 
studies of mechanical circulatory support. Notably, there is experimental evidence for 
the feasibility of such an approach. Injection of large quantities of 6 to 14 !lm plastic 
microspheres into the left main coronary arteries in calves resulted in elevated L VP end 
diastolic, reduced SV, CO, mean ejection rate, and left ventricular ejection time, and 
produced widespread microinfarcts through the left ventricle93 • Similarly, daily injection 
of 37 to 70 !lm polystyrene microspheres into the left coronary artery of 5 calves resulted 
in diminished cardiac function, marked reductions in CO, and significant increases in 
LAps3 • 
To study acute and chronic effects of LVADs on clinical, functional, histological, and 
molecular markers of myocardial remodeling during heart failure and mechanical 
circulatory support, Aim #2 was developed to characterize a bovine model of chronic, 
ischemic left ventricular failure. Clinically relevant heart failure was defined by a 
reduction of ejection fraction by greater than 40%, changes in ventricular geometry, 
hemodynamic imbalance, end-organ hypoperfusion, and histopathological myocardial 
changes. Results will assist in guiding future investigation into effects of acute and 
chronic mechanical circulatory support in a large-animal model of chronic cardiac 
pathology. 
The utility of this model extends beyond this project and our laboratory. Our results 
contribute a novel and clinically relevant, large-animal heart failure model for other 
investigators, government agencies, and industry. 
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II. Materials and Methods 
Animals 
Male Jersey, K-bar, and mixed-breed calves (n=15, 96±8 kg) were used. All animals 
received humane care and were handled in accordance with National Institutes of Health 
and University of Louisville animal care committee guidelines. Experimental procedures 
followed the University of Louisville Institutional Animal Care and Usage Committee 
approved protocol #09080. 
Anesthesia 
Twenty-four hours prior to coronary microembolization, oral Atenolol (50 mg) was 
administered to decrease post-micro embolization mortality as previously reported95 • 
Animals were pre-anesthetized with Atropine (30 mg) and prepared for strict aseptic 
surgery. Prophylactic intravenous Cefazolin (15 to 20 mg/kg) was administered. In the 
catheterization laboratory, general anesthesia was administered with Isoflurane (3-5%) 
and room air. Tidal volume and respiratory rate were adjusted to maintain arterial 
oxygen saturation above 90%. An intravenous catheter was placed in the marginal ear 
vein for administration of normal saline (5 to 10 mllkg/hour) to maintain arterial blood 
pressure. An intraarterial catheter was placed in the marginal ear artery to monitor 
arterial blood pressure. Surface electrocardiographic leads were sutured to the skin in a 
lead II configuration. Via modified Seldinger technique, a 7-French introducer sheath 
was introduced into the left common carotid artery. The animal was anticoagulated with 
a single bolus of intravenous Heparin (100 units/kg). 
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Cardiac Catheterization and Baseline Hemodynamics 
Under fluoroscopic guidance, a 6-French dual-tip pressure-volume conductance catheter 
(Millar Instruments, Houston, TX) was advanced from the carotid artery into the left 
ventricle for simultaneous measurement of left ventricular and aortic blood pressures. A 
30 second continuous data set was recorded at normal baseline. Approximately 45 
minutes after coronary microembolization, this procedure was repeated and a post-
embolization heart failure baseline data set was recorded. 
Cardiac Catheterization and Baseline End-Organ Blood Flow Measurement 
Under fluoroscopic guidance, a 6-French pigtail catheter was advanced from the carotid 
artery into the left ventricle for injection of 15 flm fluorescent-labeled microspheres. A 
single color of fluorescent-labeled microspheres (5.25 million micro spheres) was injected 
into the left ventricular chamber. Simultaneously, a reference blood sample was 
withdrawn from the carotid sheath at a rate of 15 mllmin for 100 seconds. The 
microsphere technique enables the precise measurement of regional blood flow in 
vascular beds of interest as previously described in Chapter IV, Section II. 
Coronary Catheterization and Microembolization 
Intravenous Lidocaine (100 mg) and Amiodarone (150 mg) were administered to prevent 
arrhythmia. Under fluoroscopic guidance, a 6-French diagnostic catheter (AL-2) was 
advanced from the carotid artery to selectively engage the left main coronary artery. 
Correct catheter placement was confirmed by coronary angiography with radio-opaque 
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contrast dye (Iothalamate Meglumine, Conray 43, Mallinckrodt, St. Louis MO) as 
needed. 
To induce global left ventricular ischemia and chronic, ischemic heart failure, 90 ~m 
polystyrene microspheres suspended in contrast dye were injected into the left main 
coronary artery. Real-time observation of electrocardiographic ST-segment changes 
were observed and confirmed myocardial ischemia, which accompanied hemodynamic 
impairment (Figure 4). 
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Figure 4: During a typical microembolization session, 90 !-tm microspheres injected 
into the left main coronary artery produced electrocardiographic changes 
characteristic of myocardial ischemia. After 45 minutes, ST-segment elevation and 
hyperacute, biphasic T-waves indicated severe ischemic myocardial injury. These 
changes were accompanied by a 25 mmHg decrease in mean arterial blood pressure 
that persisted at 60 days and indicated chronically impaired myocardial functional 
capacity. ECG, electrocardiogram 
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Over the course of 30 to 45 minutes, multiple small boluses of microspheres were 
injected until severe and sustained electrocardiographic changes were accompanied by 
impaired hemodynamics. To maintain adequate end-organ blood flow, animals were 
supported with continuous infusion of intravenous Phenylephrine, Dobutamine, and 
normal saline to effect. Animals typically exhibited a 10 to 15 mmHg rise in L VP end 
diastolic. As such, prior to awakening an intravenous bolus of Lasix (80 mg) was 
administered to promote diuresis, mitigate pulmonary effects of elevated left ventricular 
filling pressures, and promote recovery and survival. 
At the end of the procedure, catheters and sheaths were removed, and percutaneous 
access sites were closed and compressed for 30 minutes until hemostasis was achieved. 
Animals were recovered. 
Clinical Management 
Heart rate, respiratory rate, blood pressure, and ECG were monitored for 48 to 72 hours 
post-embolization. A constant rate infusion of intravenous Amiodarone (0.5-1.5 mg/min) 
was maintained for 12 to 48 hours to prevent tachyarrhythmias. A constant rate infusion 
of intravenous Nitroglycerine (800 !-lg/hour) was administered for 24 to 48 hours post-
embolization. Oral Atenolol (100 mg) was continued twice daily for three days. 
Intravenous Cefazolin (15 to 20 mg/kg) was administered for 48 to 72 hours post 
embolization. Arterial blood gases and electrolytes were monitored every 2 to 4 hours 
for abnormalities. Most animals received intravenous Lasix (0.5 to 2 mg/kg) for 
respiratory comfort every 4 to 6 hours based on the animals respiratory pattern and effort. 
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Surface ECG leads were removed when the constant rate infusions were discontinued. In 
cases of severe heart failure, oral Lasix (0.5 to 4.0 mg/kg) was continued twice daily to 
reduce pulmonary edema and respiratory distress. Blood draws were used to monitor 
electrolyte and hydration status. 
Echocardiography 
Transthoracic echo cardiograms were measured at baseline, weekly for 60 days during the 
progression of heart failure, and while anesthetized during an acute terminal study with 
the chest open. A Phillips iE-33 machine with S8-3 ultrasound probe was used to obtain 
2-dimensional echocardiographic recordings. Parasternal views were used to obtain 
images. Left ventricular ejection fraction, and end-systolic and end-diastolic volumes 
were determined from the apical four-chamber view with a modified Simpson technique 
(summation of discs). Target left ventricular dysfunction was defined as a reduction in 
left ventricular ejection fraction greater than 40%. 
Terminal Study 
Sixty days after microembolization, a terminal study was performed to measure the 
hemodynamic severity of heart failure and to harvest tissues for histology and molecular 
analyses. Anesthesia was induced and maintained as described in Chapter IV, Section II. 
The animal was placed on the operating table in right lateral recumbency. Fluid-filled 
arterial and venous catheters were placed in the left carotid artery and jugular vein for 
blood sampling. A left thoracotomy was performed. Ribs #4 and #5 were resected. The 
pericardium was opened. An open-chest echocardiogram was performed. 
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A single-tip, high-fidelity micromanometer catheter (Millar Instruments, Houston, TX) 
was placed in the aorta and a dual pressure-volume conductance catheter (Millar 
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into 
the left ventricle for simultaneous measurement of aortic, left atrial, and left ventricular 
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was 
placed around the pulmonary artery to measure cardiac output. A silicone catheter (7-
French, Access Technologies, Skokie, IL) was implanted in the left atrial appendage 
chamber for injection of 15 /lm fluorescent-labeled polystyrene microspheres. The depth 
and angle of catheter entry parallel to the surface of the left atrial appendage ensured that 
the catheter did not interfere with mitral valve function. 
Experimental Design 
In each animal, blood pressure and flow waveforms were recorded for 30 seconds to 
determine the hemodynamic severity of heart failure. A single color of fluorescent-
labeled micro spheres (5.25 million microspheres) was injected into the left atrial catheter. 
Simultaneously, a reference blood sample was withdrawn from the arterial line at a rate 
of 15 mllmin for 100 seconds. The microsphere technique enabled the precise 
measurement of regional blood flow in vascular beds of interest as described in Chapter 
IV, Section II. 
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Quantification of Microspheres and End-Organ Blood Flow 
At the completion of the study, while under anesthesia, euthanasia was performed with a 
fatal intravenous bolus injection of Beuthanasia-D Special (1 mllS kg). The heart was 
removed and photographed. The ventricles were sectioned into a multi-level map (Figure 
7). One to two gram tissue sections from the left ventricular free wall, right ventricular 
free wall, interventricular septum, left ventricular epicardium, mid-myocardium, and 
endocardium, kidney, liver, spleen, small bowel, lung, skin, skeletal muscle, brainstem, 
cerebellum, and frontal lobe were collected. Tissue samples and reference blood samples 
were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion and counting 
of fluorescent microspheres using flow cytometry and calculation of tissue specific blood 
flows in mllmin/g of tissue. Regional myocardial blood-flow maps were constructed on a 
piece-by-piece basis. 
Histology 
Triphenyltetrazolium chloride (TTC) staining was performed on gross cross-sections of 
hearts to approximate the amount of infarcted myocardium. Microscopic myocardial 
histology was performed on left ventricular and right ventricular samples obtained from 
heart failure animals (n=9) and compared to myocardium from normal control animals 
(n=8). Paraffin-embedded tissues were sectioned at 4 fA,m, de-paraffinized, rehydrated, 
and stained. Regional myocardial fibrosis was quantified with Masson's trichrome 
staining as the ratio of area occupied by collagen stain to the area of myocardium 
sampled 101. Regional myocyte size was determined with FITC-conjugated wheat germ 
agglutinin and DAPI (Molecular Probes, Invitrogen, Carlsbad, CA) nuclear co-staining to 
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delineate the cell membrane in 100 cross-sectional cells with centrally located nuclei102. 
Regional total cardiac apoptosis was determined with the DeadEnd Fluorometric TUNEL 
System (Promega, Madison, WI), which catalytically incorporates fluorescein-12-dUTP 
at DNA strand breaks in cells actively undergoing programmed cell death102• Nuclei 
were counterstained with DAP!. Myocyte-specific apoptosis was determined with a 
combination of Texas Red-conjugated wheat germ agglutinin, TUNEL, and DAPI 
staining. Images were viewed with epifluorescence microscopy (Nikon TE2000) and 
analyzed with Metamorph Imaging Software. For each histological stain, a minimum of 
three fields were analyzed from each myocardial region. 
Data Reduction 
All transducers were pre- and post-calibrated against known physical standards to ensure 
measurement accuracy. Calibration curves for the volume conductance catheter were 
constructed using static and dynamic tests pre- and post-experiment. Hemodynamic data 
were collected at 400 Hz, signal conditioned, and AID converted for digital analysis 
using our GLP compliant data acquisition system75 • 
To determine the hemodynamic severity of heart failure, pressure and flow waveforms 
were used to derive HR, LVPend diastolic, LVPpeak systolic, ±dP/dt , AoPmean, AOPsystolic, 
AOPdiastolic, AOPpulse, HR x LVPpeak systolic, PAF as an index of CO, and CO/animal weight. 
Hemodynamic indices were calculated on a beat-to-beat basis for each 30 second data set 
with the Hemodynamic Evaluation and Assessment Research Tool (HEART) program77 
developed in Matlab (Version 6.5, MathWorks, Natick, MA). All analyzed beats in each 
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data set (approximately 30 to 50 beats/30 second data set) were averaged to obtain a 
single representative mean value for each calculated variable. 
Statistics 
GraphPad, version 4.00 (Prism, La Jolla, CA) was used to perform statistical analyses 
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed 
to compare weekly echocardiographic measurements. Unpaired student t-tests were 
performed to compare acute hemodynamics, chronic hemodynamics, end-organ blood 
flow, and histological findings between heart failure animals and normal animals (n=9)15. 
Paired student t-tests were used to compare histological findings between the left and 
right ventricles within normal control and heart failure animals. All analyses were two-
tailed, and a p-value<0.05 (95% confidence) was considered statistically significant. All 
data are presented as mean±standard error. 
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III. Results 
Survival, Clinical Findings, and Data Collected 
Fifteen animals underwent selective left main coronary artery microembolization. 
Hemodynamics in 12 animals were studied at baseline prior to coronary 
microembolization and 45 minutes after microembolization. Nine animals survived the 
initial embolization period. These animals developed tachycardia, arrhythmias, murmurs, 
tachypnea, chronic coughing, and dyspnea on exertion. Serial echocardiography was 
performed weekly until termination. Of the nine animals, eight survived 60 days at 
which time an elective, terminal study was performed to measure the hemodynamic 
severity of heart failure, measure end-organ blood flow, and collect tissues. 
Echocardiography 
Target severity of chronic heart failure (approximately 40 % reduction in ejection 
fraction) was achieved in eight animals. Figure 5 demonstrates M-Mode images at 
baseline (A) and 60 days after left main coronary microembolization (B) in the same 
animal. Increased heart rate, hypokinetic left ventricular wall motion, and marked 
dilatation of the left ventricular chamber are noted. 
Left ventricular ejection fraction decreased in all animals (Figure 5 C) from a baseline 
conscious value of 81±5% to a final conscious value of 43±13% (p<O.OI vs. baseline) 
and final anesthetized value of 29±1O% (p<0.05 vs. final conscious). Left ventricular 
end-diastolic and end-systolic volumes increased in all animals (Figure 5 D) from 
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baseline values of 115±45 ml and 22±1O ml to final values of 173±28 ml (p<0.05 vs. 




'Heart Failure (60 Days) 
- End-Oiastolic 
"' End-Systolic 
'p<O.05 vs. baseline (8) 





.... Embollized Awake (n=9) 
Gl Embollzed Anesthetized (n=8) 
"p<O.01 vs. baseline (8) 
tp<O.05. day 63 vs. terminal ane eli.zed (T) 
14 28 42 
Day 
66 T 
Figure 5 A, B: M-mode images at baseline and 60 days after coronary microembolization 
in the same animal. Left ventricular dilatation and systolic dysfunction are present. C: 
Coronary microembolization reduced the left ventricular ejection fraction by 
approximately 50%. D: End diastolic and end-systolic left ventricular dilatation was 
present. 
Acute and Chronic Hemodynamics 
Table 5 demonstrates hemodynamic variables measured at baseline and 45 minutes after 
left main coronary microembolization. Hallmark hemodynamic changes associated with 
systolic dysfunction were noted despite aggressive pharmacological support of 
hemodynamics. A significant increase in L VP end diastolic (p<O.OOO 1) was accompanied by 
a significant decrease in -dP/dt (p=O.04) and trends toward decreased LVPpeak systolic 
(p=O.07), AoPmean (p=O.l4), AOPsystolic (p=O.09), and AOPdiastolic (p=0.20). 
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Table 6 demonstrates hemodynamic variables measured at 60 days after the induction of 
heart failure. When compared to normal calves of smaller size (n=9, mean: 76.1 kg)IS, 
calves that underwent coronary microembolization exhibited hemodynamic changes 
associated with left ventricular dysfunction. A trend toward a compensatory tachycardia 
accompanied significantly decreased LVPpeak systolic (p=0.008), -dP/dt (p<O.OOI), AoPmean 
(p<0.002), AOPsystolic (p<0.002), AOPdiastolic (p=0.004), and CO/weight (p<0.001). A 
change in L VP end diastolic did not occur and may have been due to ongoing diuresis used to 
treat respiratory distress associated with pulmonary edema. 
Baseline Post-Embolization (45 min) 
(n=12) {n=12} p-value 
HR (bpm) 61±4 66±3 0.37 
LVP end diastolic (mmHg) 15±1 23±2 <0.0001 
LVPpeakSysto1ic (mmHg) 106±8 '95±3 0.07 
+dP/dt (mmHg/s) 1,11:6±230 930±70 0 .35 
-dP/dt (mmHgls) -1,890±243 -1 ,29'5:1:66 <0.05 
AoPmean (mmHg) 90±9 80±4 0.14 
AOPsysto1iC (mmHg) 106±8 94±4 0.09 
AOPdiastoliC(mmHg) 76±966±5 0.20 
AOPpuise (mmHg) 31±2 28±2 '0.93 
HR X LVPpeaksystolic (bpm X mmHg) 6,567±824 6,306±448 0.74 
Table 5: Hemodynamics 45 minutes post-embolization. HR, heart rate; LVP, left 
ventricular pressure; AoP, aortic pressure 
Baseline Heart Failure (60 Days) 
{n=9~ {n=8} p-value 
HR (bpm) 78±4 88±7 0.24 
LVP end diastolic (mmHg) 16±2 17±2 0.68 
LVP peak systolic (mmHg) 103±3 83±6 <0.'01 
+dP/dt (mmHg/s) 1,252±144 1,193±195 0.80 
-dP/dt (mmHg/s) -2,527±306 -984±95 <0.001 
AoPmean (mmHg) 90±4 '62±7 <0.01 
A:OPsysto1ic (mmHg) 105±3 78±7 <'0.01 
AOPdiastolic (mmHg) 73±4 51±6 <0.01 
AOPpulse (mmHg) 32±2 28±3 0.22 
HR X LVPpeakSystolic (bpm X mmHg) .s,014±540 7,174±586 0.29 
CO (Umin) 8.1±'O.4 7.4±1.0 0.47 
Weight (kg) 7,8±4 130±14 <0.01 
COlWeight (mllmin/kg) 105±5 61 ±9 <0.001 
Table 6: Hemodynamics 60 days post-embolization. HR, heart rate; LVP, left 
ventricular pressure; AoP, aortic pressure; CO, cardiac output 
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End-Organ Blood Flow 
Figure 6 demonstrates end-organ blood flow in normal and chronic heart failure animals. 
Reduced blood flow was noted in nine of ten vascular beds studied. Blood flow 
reductions were quantitatively large in the kidneys, lung, brainstem, and frontal lobe, but 
were not statistically different in any organ. 
Norma,1 Control (n=6) 











Figure 6: Sixty days after coronary microembolization, end-organ blood flow 
decreased systemically. However, blood flow reductions were not statistically 
significant in any organ and may have indicated that adequate compensation enabled 
animals to maintain end-organ perfusion in the lower range of normal. 
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Regional Myocardial Blood Flow 
Figure 7 demonstrates gross heart sections and a multi-level, regional myocardial blood 
flow map in one animal 60 days after microembolization (A-C). This animal received 
the majority of the dose of micro spheres in the left circumflex coronary artery. As such, 
a large superior and posterolateral myocardial infarction was noted in the gross heart 
specimen. Small infarcts are noted dispersed throughout the left ventricular free wall and 
interventricular septum. 
The myocardial flow maps and regions of reduced myocardial blood flow corresponded 
well with the area of gross infarction. Regional right ventricular and anterior 
interventricular blood flow was largely unaffected. 
Global myocardial hypoperfusion was noted (Figure 7 D, E). Left ventricular free wall 
blood flow decreased significantly from control values in normal animals of O. 79±0.09 
mllminlg to 0.34±0.05 mllminlg (p<O.Ol) in heart failure animals. Right ventricular free 
wall blood flow tended to decrease from control values in normal animals ofO.69±0.08 
mllminlg to 0.50±0.1 0 mllminlg (p=0.17) in heart failure animals. Similar reductions 
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F igure 7 A-C: TTC-stained gross heart sections and a multi-level, regional myocardial 
blood flow map in one animal demonstrated a large superior and posterolateral 
myocardial infarction. The dose of mlcrospheres was injected selectively into the left 
circumflex coronary artery. D, E: Global myocardial hypoperfusion was noted in heart 
failure animals versus normal control animals. 
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Histology 
Figure 8 demonstrates the gross and microscopic appearances and percentage of fibrosis 
in the left and right ventricles in control and microembolized hearts stained with TTC and 
Masson's Trichrome, respectively. The heart of a control animal appeared uniform in 
color (Top Left Panel). The left ventricular chamber was small. 
One week after left main coronary microembolization, the left ventricle exhibited mild 
dilatation and large and diffuse islands of unconsolidated coagulative necrosis (Middle 
Left Panel). The right ventricle appeared normal. 
Eight weeks after coronary microembolization, the left ventricle exhibited marked 
dilatation with free-wall thinning and consolidation of infarcted myocardium (Bottom 
Left Panel). Although the right ventricular wall appeared grossly normal, marked right 
ventricular dilatation was noted. 
Microembolized left vlentricular myocardium contained more fibrosis than normal, 
control left ventricle (39±1O% vs. 4±2%, p<O.OOOI). Right ventricular myocardium in 
microembolized animals also contained more fibrosis than normal, control right ventricle 
(11±5% vs. 6±2%, p<O.05). In microembolized hearts, left ventricular myocardium 
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Figure 8, Left: Microembolized myocardium exhibited significant coagulative 
necrosis at 1 week, and consolidated infarction after 8 weeks. A: Right ventricular 
myocardium from a microembolized heart exhibited minimal fibrosis. B: Left 
ventricular myocardium from a microembolized heart exhibited diffuse infarction. 
Bar Graph: Compared to normal control hearts, microembolized hearts contained 
significantly elevated fibrosis globally. 4X, black bar = 1,000 f1.m 
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Figure 9 demonstrates myocyte size in the left and right ventricles in control animals and 
animals that underwent coronary microembolization. Myocytes in the left ventricle of 
rnicroembolized hearts were grossly hypertrophic as compared to left ventricular 
myocytes in normal, control left ventricle (E vs. C, 343±99 !-lm2 vs. 146±70 !-lm2, p<O.Ol) 
and right ventricular myocytes in the same animal (E vs. D, 343±99 !-lm2 vs. 205±104 
!-lm2, p<0.05). Myocytes in the right ventricle of microembolized hearts were also 
hypertrophic as compared to normal, control right ventricle (D vs. B, 205±104 !-lm2 vs. 
A • Control (n=8) 
Embolized (n=9) 
* p<O.01 YS. control 
tp<O.05 vs. RV 
Right Ventricle Left Ventricle 
Control 
Heart Failure (60 Days) 
Figure 9 A: Significant myocyte hypertrophy was observed in the left and right ventricles 
of microembolized hearts as compared to normal control animals. Within 
microembolized hearts, left ventricular myocytes were significantly larger than right 
ventricular myocytes. B, C: Right and left ventricle from normal control animals. D, E: 
Right and left ventricle 60 days after coronary rnicroembolization. 20X, white bar = 200 
!-lm 
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Figure 10 demonstrates the incidence of total cardiac cell apoptosis in the left and right 
ventricles in control and microembolized hearts. The total apoptosis rate in the left and 
right ventricles of microembolized hearts was markedly increased as compared to normal, 
control left and right ventricle (left ventricle: 0.63±0.41 % vs. 0.12±0.1 0%, p<O.Ol ; right 
ventricle: 0.45±0.34% vs. 0.14±0.12%, p<0.05). Within microembolized hearts, the 
apoptosis rate in the left ventricle trended toward an increase as compared to the right 
ventricle (p=0.08). 
A 
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Figure 10, A: Total cardiac apoptosis increased significantly in the left and right 
ventricles of micro emboli zed hearts as compared to normal control hearts. B, C: DAPI 
co-nuclear stain. D, E: FITC TUNEL+ stain. F, G: DAPI plus FITC overlay. Cyan 
nuclei indicate TUNEL+ cells. lOX, white bar = 400 flm 
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Figure 11 demonstrates the incidence of myocyte-specific apoptosis in the left ventricle 
of control and rnicroembolized hearts. Myocyte apoptosis was markedly increased in 
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Figure 11, A: Myocyte-specific apoptosis increased significantly in microembolized 
hearts as compared to normal control hearts. B, C: Texas Red-conjugated wheat germ 
agglutinin stain. D, E: DAPI co-nuclear stain. F, G: FITC TUNEL+ stain. H, I: Texas 
Red plus DAPI plus FITC overlay. Cyan nuclei indicate TUNEL+ cells. I: A single 
myocyte undergoing apoptosis is seen in the inset. In the upper right comer, a small nest 
ofTUNEL+ cells are not myocytes and may be inflammatory cells in the extracellular 
matrix that are participating in ischemic, inflammatory-mediated remodeling. 20X, white 
bar = 200 "",m 
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IV. Conclusions 
We have developed a novel bovine model of chronic, ischemic heart failure. 
Specifically, injection of 90 [-tm micro spheres into the left main coronary artery 
produced: 1) acute electrocardiographic changes consistent with severe ischemic 
myocardial injury, 2) a clinical profile consistent with left ventricular failure, 3) acute and 
chronic hemodynamic changes associated with systolic dysfunction, 4) a sustained and 
stable 50% reduction in left ventricular ejection fraction, 5) left ventricular dilatation, 6) 
reduced regional myoeardial and systemic end-organ blood flow, 7) 40% fibrosis of the 
left ventricle, 8) global myocyte hypertrophy, and 9) increased total cardiac and myocyte-
specific apoptosis. Our results establish the feasibility and validity of a bovine model of 
chronic, ischemic heart failure that shares many phenotypic similarities with human heart 
failure. 
In summary, the calf is the industry standard for preclinical testing of cardiac assist 
devices. As such, this clinically relevant model is an appropriate platform to test acute 
and chronic (patho )physiological responses to LV ADs and other translational therapies. 
This model may prove useful to develop support strategies to specifically promote 




Aim #3: PARTIAL vs. FULL SUPPORT OF THE FAILING LEFT VENTRICLE 
WITH A CONTINUOUS-FLOW LV AD 
I. Introduction 
If combined, the benefits of a full-support device implanted with a minimally invasive 
surgical approach may expand the target patient population for myocardial recovery with 
an LV AD. Original in silico work suggested that partial support of a failing ventricle 
with a continuous-flow LV AD may increase cardiac output and lower ventricular filling 
pressures62 . The greatest hemodynamic benefits were predicted for less-dilated and less-
dysfunctional hearts. Computer simulations were validated in an acute bovine model of 
cardiac dysfunction in which continuous partial support at a rate of 3 Llmin decreased left 
atrial pressure by 6 to 7 mmHg and increased cardiac output by greater than 1 Llmin62 . 
As LV ADs are miniaturized, limited thoracotomy, subxiphoid access, thoracic keyhole 
access, placement of surface devices, or percutaneous implantation may permit earlier 
therapy in less sick patients. Minimally invasive implantation may increase acceptance 
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by patients and physicians who are more likely to refer patients for less-invasive surgical 
therapies 71. As a result, earlier intervention in less-sick patients may increase the public-
health impact of mechanical circulatory support. Additionally, these operative 
approaches often do not require cardiopulmonary bypass 103 . As a result, less 
postoperative coagulopathy may reduce postoperative bleeding and blood transfusions 
which playa role in right ventricular dysfunction and infection with L V ADs 104. 
Similarly, early clinical data suggest that partial support does not dramatically increase 
cardiac output and right ventricular overload and right ventricular failure are unlikelyl4. 
Recently, a number of partial support LV ADs have been developed. F or example, the 
CircuLite Synergy Pocket Micro-Pump (CircuLite Incorporated, Saddle Brook, NJ) is a 
small continuous-flow LV AD the size of an AA battery (49 mm, outer diameter 14 mm, 
25 g)26. The CircuLit(~ LV AD is implanted via a miniature, right-sided thoracotomy 
without extracorporeal circulation and continuously unloads 2.5 to 3.0 Llmin of blood 
from the left atrium into the subclavian artery. 
Less-invasive devices such as the Synergy pump provide important technical benefits. In 
the event of pump thrombosis, device failure, or pump-pocket infection, the device may 
be easily and rapidly exchanged through the original infraclavicular incision without 
entering the chest. An additional and unique advantage is that the implantation procedure 
involves a right-sided thoracotomy in which it is unlikely that adhesions will form in the 
anterior mediastinum ,md complicate median sternotomy if heart transplantation is 
indicated. A future design that obviates entrance into the thorax will include an inflow 
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graft placed percutaneously through the subclavian vein and advanced through the 
interatrial septum into the left atrium. As with the current design, the outflow graft will 
be sewn to the subclavian artery. With this approach, the need for a thoracotomy will be 
eliminated, and the infraclavicular incision will be the only incision necessary to implant 
the entire system I 05. This approach will likely further increase acceptance by patients and 
referring physicians. 
Initial results with the CircuLite device are encouraging. In an ongoing multicenter 
E I·· I . 114 26 105 b I . h I I' 'th . uropean c mIca tna ' , , am u atory patIents on t e transp ant 1st WI motrope-
independent NYHA class IIIB or IV A heart failure and preserved end-organ function 
demonstrated hemodynamic improvements over a 3-month follow-up (ongoing maximum 
support duration of eight months)14, 26,105. Partial hemodynamic recovery included 
significant increases in cardiac index from 2.0±0.4 to 2.8±0.6 Llminlm2, an increase in 
AoPmean from 67±8 to 80±9 mmHg, and a reduction in pulmonary capillary wedge 
pressure from 30±5 to 18±5 mmHg26. N-terminal fragment pro-brain natriuretic peptide 
was significantly redueed from 6,452±5,470 to 3,209±2,379 pg/ml105 and suggested a 
reduction in myocyte stress. As predicted, right heart failure was not a clinical challenge 
with the CircuLite pump. During support, the acute increase in cardiac output ranged 
from 1.0 to 1.5 Llmin and did not overload the right ventricle l4. 
These preliminary results in humans suggest that partial support is not only safe but may 
also be an effective strategy to support less dysfunctional hearts. These findings 
encourage basic scientific investigation to further validate and improve this approach. 
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For example, in the current European trial, implants of the CircuLite pump were 
performed primarily to demonstrate long-term safety and efficacy as a bridge-to-
transplant therapy. As such, this device has not yet been implanted with the specific goal 
of myocardial recovery. 
Accordingly, experimental studies will be necessary to define the clinical utility of partial 
circulatory support for the treatment of early stages of heart failure. A major undertaking 
will be to evaluate whether a protocol that includes partial unloading may promote 
myocardial recovery and in which patient population(s). As a first step, it will be 
important to understand how the left ventricle should be unloaded in preparation for 
prolonged partial support. The major goal of Aim #3 was to examine acute responses to 
partial vs. full support of the failing left ventricle with a continuous-flow LVAD. The 
effect of continuous unloading on the myocardial supply/demand relationship was studied 
in animals with chronic, ischemic heart failure. Standard indices of cardiovascular 
performance and regional myocardial blood flow were measured during each support 
mode. Implications for reverse myocardial remodeling and myocardial recovery were 
considered. Results of this study will assist in guiding future investigation into the 
chronic effects of continuous-flow mechanical circulatory support in large-animal models 
of chronic cardiac pathology. 
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II. Materials and Methods 
Animals 
Male Jersey, K-bar, and mixed-breed calves from Aim #2 that had undergone left main 
coronary artery embolization and exhibited signs of chronic, ischemic heart failure (n=9, 
130±13 kg) were used. All animals received humane care and were handled in 
accordance with National Institutes of Health and University of Louisville animal care 
committee guidelines. Experimental procedures followed the University of Louisville 
Institutional Animal Care and Usage Committee approved protocol #09080. 
Anesthesia 
Animals were pre-anesthetized with Atropine (30 mg) and prepared for acute, non-sterile 
surgery. In the operating room, general anesthesia was administered with Isoflurane (3-
5%) and room air. The animal was placed on the operating table in the right lateral 
recumbency. Tidal volume and respiratory rate were adjusted to maintain arterial oxygen 
saturation above 90%. Fluid-filled arterial and venous catheters were placed in the left 
carotid artery and jugular vein for blood sampling. A left thoracotomy was performed. 
Ribs #4 and #5 were resected. The pericardium was opened. The animal was 
anticoagulated with a single bolus of intravenous Heparin (100 unitslkg). For the 
remainder of the procedure, the ACT was maintained above 250 s with additional boluses 
of Heparin (1,000 to 2,000 units). 
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Surgical Instrumentation 
A single-tip, high-fidelity micromanometer catheter (Millar Instruments, Houston, TX) 
was placed in the aorta and a dual pressure-volume conductance catheter (Millar 
Instruments, Houston, TX) was advanced from the left atrium across the mitral valve into 
the left ventricle for simultaneous measurement of aortic, left atrial, and left ventricular 
blood pressures. A transit-time ultrasonic flow probe (Transonics, Ithaca, NY) was placed 
around the pulmonary artery to measure cardiac output. In six animals, a silicone 
catheter (7-French, Access Technologies, Skokie, IL) was advanced in the left atrial 
appendage chamber for administration of 15 ~m fluorescent-labeled polystyrene 
micro spheres. The depth and angle of catheter entry parallel to the surface of the left 
atrial appendage ensured that the catheter did not interfere with mitral valve function. 
L V AD Implantation 
A continuous-flow LV AD (HeartWare HV AD n=4, Thoratec HeartMate II n=5) was 
implanted without cardiopulmonary bypass. The outflow graft was anastomosed to the 
descending aorta. The left ventricular apex was cored and cannulated. The device and 
outflow graft were de-aired. A transit-time ultrasonic flow probe (Transonics, Ithaca, 
NY) was placed around the outflow graft to measure LV AD flow. 
Experimental Design 
In each animal, blood pressure and flow waveforms were recorded during Heart Failure 
Baseline (pump off, outflow graft clamped), Low Partial Support (~1.5 Llmin support, 
aortic valve opening every beat), High Partial Support (~3 Llmin support, aortic valve 
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opening every beat), and Full Support (-5 Llmin, aortic valve maintained closed, left 
ventricle maximally unloaded). Heart Failure Baseline and support modes for each 
device were maintained for 10 minutes each to achieve steady-state conditions prior to 
collection of 30 second data sets. During each condition, a single color of fluorescent-
labeled microspheres (5.25 million micro spheres) was injected into the left atrial catheter. 
Simultaneously, a reference blood sample was withdrawn from the arterial line at a rate 
of 15 mllmin for 100 seconds. The microsphere technique enabled the precise 
measurement of regional myocardial blood flow as described in Chapter IV, Section II. 
In one animal, ventricular fibrillation occurred prior to the implantation of the LV AD. 
Open-chest cardiac massage was performed. Multiple shocks were attempted but 
defibrillation was unsuccessful. However, after implantation and operation of the LV AD 
at full support for approximately 20 minutes, the animal was successfully defibrillated. 
The estimated ischemic time was approximately 60 minutes. Prior to data collection, it 
was noted that substantial ST -segment elevation accompanied a coronary hyperemia. As 
a result, the regional myocardial blood flow data from this animal was not used. 
Quantification of Microspheres and Regional Myocardial Blood Flow 
At the completion of the study, while under anesthesia, euthanasia was performed with a 
fatal intravenous bolus injection of Beuthanasia-D Special (1 mIlS kg). The heart was 
removed. One to two gram tissue sections from the left ventricular free wall, right 
ventricular free wall, interventricular septum, and left ventricular epicardium, mid-
myocardium, and endocardium were collected. Myocardial samples and reference blood 
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samples were sent to IMT/Stason Laboratories (Irvine, CA) for automated digestion, 
counting of fluorescent micro spheres with flow cytometry, and calculation of tissue 
specific blood flows in mllminlg of tissue. 
Data Reduction 
All transducers were pre- and post-calibrated against known physical standards to ensure 
measurement accuracy. Calibration curves for the volume conductance catheter were 
constructed using static and dynamic tests pre- and post-experiment. Data were collected 
at 400 Hz, signal conditioned, and AID converted for digital analysis using our GLP 
compliant data acquisition system 75. 
To determine hemodynamic performance during each support mode, pressure and flow 
waveforms were used to derive LVADF, HR, SV, PAF as an index ofCa, LAP, LVPend 
diastolic, L VP peak systolic, :±:dP / dt, HR x L VP peak systolic, AoP systolic, AoP diastolic, AoP mean, 
AoP pulse. Myocardial vascular resistance was calculated as AoP mean/region-specific 
myocardial blood flow. Hemodynamic variables were calculated on a beat-to-beat basis 
for each 30 second data set with the Hemodynamic Evaluation and Assessment Research 
Tool (HEART) program77 developed in Matlab (Version 6.5, MathWorks, Natick, MA). 
All analyzed beats in e:ach data set (approximately 30 to 50 beats/30 second data set) 
were averaged to obtain a single representative mean value for each calculated variable. 
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Statistics 
GraphPad, version 4.00 (Prism, La Jolla, CA) was used to perform statistical analyses 
and plot data. One-way repeated measures ANOVA with Tukey post-test was performed 
for each hemodynamic index, region of myocardial blood flow, and myocardial blood 
flow normalized to HR x LVPpeak systolic to compare Heart Failure Baseline, Low Partial 
Support, High Partial Support, and Full Support modes within each animal. An unpaired 
student t-test was perDJrmed to compare the myocardial blood supply/demand ratio 
between normal and heart failure animals at baseline and during each level of support. 
All analyses were two-tailed, and a p-value<0.05 (95% confidence) was considered 
statistically significant. All data are presented as mean±standard error. 
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III. Results 
Table 7 demonstrates that in animals with chronic heart failure, as the level of support 
with a continuous-flow LVAD increased, the cardiac and systemic arterial hemodynamic 
profile progressively changed. An increase in continuous support increased CO in a 
dose-dependent mann(~r. The observed increases were small and were not quantitatively 
different between support modes. HR did not change during LV AD support. 
Left Ventricular Hemodynamics 
As in normal animals, left ventricular pressures demonstrated the most robust changes. 
The progressive increase in continuous support significantly decreased LAP (p=O.02), 
L VP end diastolic (p<O.O 1), and L VP peak systolic (p<O.O 1) with a dose-dependent response. 
Reductions were greatest and indicated maximum unloading during Full Support. 
Smaller reductions were observed during partial-support modes. Full Support 
significantly reduced +dP/dt (p<O.OOl) and -dP/dt (p=O.03). However, partial-support 
modes did not affect ±dP/dt. 
As seen in normal animals, during Full Support the variation between end-systolic and 
end-diastolic pressures decreased to non-physiologically low values and resulted in 
chronic closure of the aortic valve. In this situation, the average L VPpeak systolic (57±9 
mmHg) did not exceed the AOPdiastolic (67±6 mmHg). As a result, the aortic valve 
remained closed, and HR x L VP peak systolic decreased significantly (p<O.OO 1) to values that 
are not seen in normal animals. This finding indicated that unloading the heart with a 
68 
continuous-flow LVAD dramatically reduced myocardial metabolic demands and with a 
response dependent on the degree of support. 
Arterial Hemodynamics 
Systemic arterial pressures exhibited more robust changes than were observed in normal 
animals. As continuous support increased, AOPsystolic did not change. However, 
AoP diastolic increased significantly by 16 mmHg (p<O.OO 1) and AoP mean trended toward an 
increase of 8 mmHg (p=O.II). AoP pulse did not change during Low Partial Support. 
However, during High Partial Support, AOPpulse decreased significantly from 27±3 to 
15±2 mmHg (p<O.OOOI), which was comparable to the reduction observed in normal 
animals during Full Support. Importantly, during Full Support, the arterial pulse pressure 
was significantly reduced from 27±3 to 5±1 mmHg (p<O.OOOI). In contrast, during Low 
Partial Support, AoP pulse did not change from Heart Failure Baseline. 
Myocardial Blood Supply/Demand Relationship 
In animals with chronic heart failure, continuous support of the left ventricle did not 
affect right ventricular myocardial vascular resistance or blood flow. However, in the left 
ventricle and interventricular septum, increasing levels of continuous support 
significantly reduced the cardiac workload, and increased the myocardial vascular 
resistance (Table 8) with a dose-dependent response. However, the increase in vascular 
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Table 7: Hemodynamics during partial vs. full support of the failing left ventricle with a continuous flow LV AD. LVADF, left ventricular 
assist device flow; HR, heart rate; LV SV, left ventricular stroke volume; P AF, pulmonary artery flow; LAP, left atrial pressure; L VP, left 
ventricular pressure; AoP, aortic pressure; *p<O.05, support mode vs. Heart Failure Baseline; tp<O.05, support mode vs. Low Partial 
Support; tp<O.05, support mode vs. High Partial Support 
blood flow did not change (Table 9). Vascular resistance and blood flow in the 
epicardial region did not change. Likely, the coronaries and large coronary arterioles 
were less responsive than in normal control animals, in which large increases in 
epicardial vascular resistance were observed. 
n-5 RV LV Septum Epicardium Mid-Myocardium Endocardium 
(mmHg/ml/mln/l!) (mmHg/ml/mln/l!) (mmHg/ml/mln/g) (mmHg/ml/min/g) (mmHg/ml/min/gl (mmHg/ml/mln/g) 
ANOVA e-value 1'-0.98 12-0.04 12-0.01 12-0.61 12<0.01 12=0.31 
Heart Failure Baseline 1.75±29 164±20 136±22 160±27 140±21 199±52 
Low Partial Support :L67±25 187±45 141±17 168±29 159±27 197±42 
High Partial Support :L75±12 206±34 170±17 200±33 172±23 252±63 
FuJI Support :L67±13 249±25* 194±24*t 194±24 217±20*t 217±20 
Table 8: Regional myocardial vascular resistance during partial vs. full support of the failing 
left ventricle with a continuous flow LV AD. RV, right ventricle; LV, left ventricle; *p<O.05, 
Full Support vs. Heart Failure Baseline; *p<O.05, support mode vs. Heart Failure Baseline; 
tp<O.05, support mode vs. Low Partial Support 
n=5 RV LV Septum Epicardium Mid-Myocardium Endocardium 
{mllminls} {ml/min/sl {ml/minlgl {mllmin/gl {ml/min/g} {ml/min/g} 
ANOVA e-value e-0 .S1 e-0 .S5 e-O.13 e-0 .S3 e-0.1S e-O.4S 
Heart Failure Baseline 0 .. 40±O.O4 O.41±O.O4 O.51±O.05 O.41±0.O2 O.49±0.05 O.39±O.O6 
Low Partial Support O.45±O.O6 O.44±0.OS O.52±O.O5 O.40±O.O6 O.49±O.OS O.40±O.O6 
High Partial Support O.43±O.O5 O.40±O.OS OA4±O.05 O.39±0.O6 OA6±O.OS O.35±O.O7 
Full Support OA5±O.03 O.45±O.O3 OAO±O.05 O.40±O.O5 O.35±O.O4 O.32±O.70 
Table 9: Regional myocardial blood flow during partial vs. full support of the failing left 
ventricle with a continuous flow LVAD. RV, right ventricle; LV, left ventricle 
To characterize the relationship between myocardial blood supply and demand, regional 
myocardial blood flow was normalized to HR x LVPpeak systolic (Table 10). During partial 
support modes, the ratio between left ventricular workload and left ventricular 
myocardial blood flow did not change. However, during full support the supply/demand 
ratio improved significantly in the left ventricular free wall (p=O.04) and interventricular 
septum (p<O.01) to values comparable to control values obtained in normal animals. 
Figure 12 summarizes the gross physiological changes observed during continuous 
unloading of the failing left ventricle. 
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Comparison to Normal Animals 
Without support, the myocardial blood supply/demand relationship in the left ventricle 
demonstrated lower values in microembolized hearts as compared to normal, control 
hearts (p=O.06). In normal hearts, support with a continuous-flow LV AD did not change 
this ratio. However, in microembolized hearts, this difference decreased with greater 
levels of support (Low Partial Support p=O.12, High Partial Support p=0.24, Full Support 
p=0.47) and indicated normalization of this relationship toward baseline values. 
n=5 
ANOVA p-value 
Heart Failure Baseline 
Low Partial Support 
High Partial Support 
Full Support 
LV /HRxLVPpeak systolic 
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Table 10: Regional myocardial blood supply/demand relationship during partial vs. full 
unloading of the failing left ventricle with a continuous flow LV AD. LV, left ventricle; 
HR, heart rate; LVP, left ventricular pressure; *p<O.05, Full Support vs. Heart Failure 
Baseline; tp<O.05, support mode vs. High Partial Support 
Normal Animals 
Cardiac Workload 
Myocardial Vascular Resistance 
I 
t 
I Myocardial Flow 
Flow/Workload 





Figure 12: During support of the failing left ventricle with a continuous-flow LV AD, cardiac 
workload decreased, and myocardial vascular resistance increased with a dose-dependent 
response. However, myocardial blood flow did not change because diastolic blood pressure 
was significantly greater during LV AD support and increased the driving force for coronary 
blood flow. As a result, the ratio between blood supply/demand improved to values observed 
in normal control animals. These findings suggested that in animals with chronic heart 
failure, the heart may have been operating at an insufficient ratio of blood supply/demand, 
and a coronary reserve was not present. 72 
IV. Conclusions 
The study of partial vs. full support of the left ventricle with a continuous-flow L V AD 
was possible in animals with cardiac pathology. Specifically, in animals with chronic, 
ischemic heart failure, 1) a systemic flow reserve was not present, and any level of 
support with a continuous-flow LV AD augmented systemic flows, 2) full support with a 
continuous-flow LV AD deranged pulsatility, whereas partial support preserved a more 
normal pulsatile profile, 3) full but not partial support of the failing left ventricle with an 
LV AD normalized the blood supply/demand relationship, 4) divergent results observed in 
normal animals vs. heart failure animals suggested that mechanical circulatory support 
studies should be conducted in large-animal models of chronic cardiac pathology. These 
results will assist to guide future in vivo studies to examine myocardial and arterial 
remodeling during chronic partial vs. full support of the heart with a continuous-flow 
LVAD. 
Systemic Effects 
In animals with chronic heart failure, a systemic flow reserve was absent. At any level of 
support with a continuous-flow LVAD, CO increased and HR did not change. This 
finding in animals with chronic heart failure was not unexpected and suggested that any 
level of flow augmentation with a continuous-flow LVAD may improve systemic arterial 
blood flow. As such, partial-support with a continuous-flow LV AD in patients with 
chronic heart failure may be a successful therapy for patients with hypoperfused end 
organs. 
73 
Effects on the Heart 
In the failing heart, full support with a continuous-flow LV AD deranged the normal 
profile of pulsatile cardiac hemodynamics. As continuous support increased, the peak 
left ventricular pressure (57±9 mmHg) dropped below the arterial diastolic pressure 
(67±6 mmHg). Insufficient preload was available to eject through the aortic valve, which 
did not open. As a result, the workload of the heart was dramatically reduced to values 
that are not observed in bovids. As in normal animals, during continuous unloading of 
the failing left ventricle, cardiac workload decreased, and myocardial vascular resistance 
increased with a signiticant dose-dependent response. However, in contrast to normal 
animals, during full support of animals with chronic heart failure, a significantly 
increased diastolic blood pressure increased coronary perfusion despite dramatically 
reduced myocardial metabolic demands. Importantly, the ratio of blood supply/demand 
improved to values observed in normal control animals. These findings suggested that in 
animals with chronic heart failure, a coronary reserve was not present and the heart may 
have been operating at an insufficient ratio of blood supply/demand. The lack of a 
change in vascular resistance and blood flow in the epicardial region during any level of 
support further suggested that coronary vasoreactivity was impaired such that coronary 
vasoconstriction did not occur, thereby ensuring adequate myocardial blood flow. 
Partial support provided inadequate reduction of myocardial metabolism and 
augmentation of diastolic blood pressure to improve the blood supply/demand 
relationship. As a result, it seems that partial support may be inappropriate as the first 
step in a multistep protocol to provide prolonged unloading toward myocardial recovery. 
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Partial Support - High Full Support 
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Figure 13, Left Myocardial Map: In animals with ischemic heart failure, the left ventricle 
operated at a reduced myocardial blood supply demand/demand ratio. Center Myocardial 
Maps: Immediately after the implantation of an LV AD, partial support was ineffective at 
rebalancing this relationship. Right Myocardial Map: However, full support normalized 
the blood supply/demand relationship throughout the left ventricle and interventricular 
septum. 
Yet, full support of the failing left ventricle with an L V AD did restore a normal 
myocardial blood supply/demand relationship (Figure 13). This novel finding suggests 
that during the immediate postoperative period after the implantation of an LV AD, the 
heart should be fully unloaded. 
This conclusion should be interpreted with caution. Full support decreased the 
HR x L VP peak systolic, an index of myocardial metabolic demand, to values that are not 
encountered in bovids. In heart failure, moderate reductions in metabolic demands are 
likely favorable, especially if the goal of treatment is myocardial recovery. However, the 
optimal reduction in cardiac metabolism which allows the heart to rest while still 
maintaining a partial workload has not been established, and excessive myocardial 
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unloading in which the heart performs too little work may induce myocardial atrophl9, 30 
and fibrosis3l , 32. 
Nonetheless, full support of the failing left ventricle by a continuous-flow LV AD has 
resulted in myocardial recovery9. Yet, myocardial recovery has most frequently been 
reported in patients that received pulsatile ventricular assistance5, 6. This critical finding 
suggests that variations in the ventricular pressure-volume relationship and cardiac 
workload may be important to reverse myocardial remodeling during heart failure. It is 
unclear how variations in stroke work affect myocardial remodeling. However, it is 
known that normal ventricular geometry depends on a consistent physiologic pressure-
volume relationship. As we have demonstrated, partial unloading preserved this 
relationship and permitted ejection though the aortic valve on every beat. These findings 
suggest a mechanism by which low native-heart volume output and loss of myocardial 
mechanical stretch may cause the heart to become a stiff and non-functional chamber. 
Therefore, it remains to be determined how long temporary full support with a 
continuous-flow L VAD is necessary before a transition to partial support is safe. Only 
after interrupting the progressive hemodynamic deterioration of heart failure, normalizing 
autonomic tone, and n:storing normal end-organ perfusion may the heart regain adequate 
function and be weaned to a partial-support mode. At that time, the reinstatement of a 
partial cardiac workload may prevent unfavorable remodeling that is characteristic of 
prolonged complete unloading of the failing left ventricle. Long-term studies in our 
model of chronic, ischemic heart failure are necessary to determine the length of full 
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support prior to a transition to partial support that may prevent myocyte atrophy and left 
ventricular fibrosis. 
Effects on the Arterial System and Emerging Novel Pathologies 
In the arteries of animals with chronic heart failure, full support of the left ventricle with 
a continuous-flow LV AD deranged the normal profile of pulsatile arterial 
hemodynamics. As continuous support increased, arterial diastolic pressure increased 
significantly, and the AoP pulse collapsed to 5± 1 mmHg, a value which is not compatible 
with life in mammals in nature28. This finding has important implications for prolonged 
LV AD therapy. Although increased diastolic blood pressure favors an increase in 
myocardial and end-organ blood flow, chronic non-pulsatile blood flow may alter the 
structure and physiological reactivity of arteries and arterioles. As the AoP pulse decreases, 
vascular resistance increases. Indeed, we have reported acute increases in vascular 
impedance in human patients in response to continuous-flow mechanical circulatory 
support 106 . Acute physiologic studies in canines have demonstrated that systemic 
vascular resistance is inversely related to AoP pulse and that systemic vascular resistance 
during non-pulsatile circulation is as much as 134% of that during pulsatile circulation107. 
Chronic studies in goats undergoing prolonged, non-pulsatile cardiopulmonary bypass 
demonstrated atrophic changes in the tunica media of the aorta that included decreased 
total smooth muscle volume, reduced cell size, changes in the constituent volume ratio of 
collagen and elastin, and decreased number of myofilaments and chromatin in smooth 
muscle cells 108. Additional studies in the same model demonstrated decreased arterial 
. . . hr' 109 d h I hr' 110 d d h vasoconstrIctIve response to norepmep me an p eny ep me an suggeste t at 
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non-pulsatile blood flow affects vascular reactivity. Overall, the net effect of prolonged 
non-pulsatile blood flow is endothelial remodeling, loss of arterial reactivity, and 
extracellular matrix remodeling, which alter arterial visco-elastic performance 
characteristics and produces stiff and unresponsive arteries. 
It may be speculated that changes to the endothelium may contribute to novel pathologies 
observed in patients with prolonged non-pUlsatile blood flow. For example, recent 
reports have documented an increased incidence in refractory diastolic hypertension57, 58, 
ischemic and hemorrhagic stroke86, acquired von Willebrand disease87, 88, and 
gastrointestinal arteriovenous malformations and bleeding89 in patients with continuous-
flow LV ADs. These cardiovascular pathologies likely share a common etiology related 
to the absence of pulsatile stretch of arteries and/or the influence of high, pulseless shear 
stress on the endothelium. Although causality and mechanism remain to be determined, 
effects of prolonged diastolic hypertension with a narrow pulse pressure on the 
vasculature (and heart) may be a limiting factor in long-term patient outcomes. 
Clinical Implications 
These findings have important clinical implications for device development, selection, 
operation, and weaning. If combined, the benefits of a full-support device implanted with 
a minimally invasive surgical approach may expand the target patient population for 
myocardial recovery with an L VAD. As LV ADs are miniaturized, limited thoracotomy, 
subxiphoid access, thoracic keyhole access, placement of surface devices, or 
percutaneous implantation may permit initial full support which is later reduced to partial 
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support. Minimally invasive implantation may increase acceptance by patients and 
physicians who are more likely to refer patients for less-invasive surgical therapies71 • 
Earlier intervention in less-sick patients may increase the public-health impact of 
mechanical circulatory support. Additionally, these operative approaches often do not 
require cardiopulmonary bypass 103. As a result, less postoperative coagulopathy may 
reduce postoperative bleeding and blood transfusions which playa role in right 
ventricular dysfunction and infection with LVADsI04. 
In summary, partial support with a continuous-flow LV AD is feasible and may preserve a 
more normal cardiac and systemic arterial hemodynamic profile. However, partial 
support may not be appropriate as the initial step in the clinical management of patients 
with chronic heart failure. Only after a period of full support may the level of support be 
reduced. Additional studies are needed to determine the duration of full support 
necessary prior to prolonged partial support. 
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CHAPTER VII 
SUMMARY AND FUTURE RESEARCH DIRECTIONS 
I. Summary of Findings 
1) Left main coronary artery microembolization induced chronic, ischemic 
heart failure in calves. A stable and reproducible large-animal model of 
chronic heart failure is possible with many phenotypic similarities to clinical 
heart failure. 
2) In normal animals and animals with chronic heart failure, full but not partial 
support with a continuous-flow LV AD deranged the physiological profile of 
pulsatile cardiac and arterial hemodynamics. 
3) In normal animals, neither full nor partial support with a continuous-flow 
L V AD affected the myocardial blood supply/demand relationship. However, 
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in animals with chronic heart failure, full but not partial support normalized 
the myocardial blood supply/demand relationship. 
4) Divergent results were observed between normal animals and animals with 
chronic heart failure. Normal animals do not reproduce the complex 
pathophysiological presentation of chronic heart failure and are not ideal for 
validation and proper translation of mechanical circulatory support 
strategies into clinical practice. 
In order to translate basic scientific findings from the bench into the clinic, an appropriate 
and clinically relevant large-animal model is necessary. We have developed a bovine 
model of chronic, ischemic heart failure that reproduces the complex pathophysiological 
presentation of functional, neurohormonal, and architectural derangements that are 
typical in chronic heart failure. This model is relevant for preclinical testing of cardiac 
devices and other translational therapies. 
In this model, complete unloading of the failing left ventricle rebalanced the myocardial 
blood supply/demand relationship. However, full-support with a continuous-flow LVAD 
dramatically changed cardiac and systemic arterial hemodynamics, which may have long-
term consequences sueh as myocardial and arterial remodeling. 
In contrast, partial support was unable to normalize the blood supply/demand 
relationship. Yet, partial support augmented systemic flows and preserved a normal 
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profile of pulsatile hemodynamics in which the aortic valve opened on every beat. 
Accordingly, why not combine the two modes of support? Our findings suggest that in 
the immediate postop~:rative period after the implantation of an LV AD, complete 
unloading of the failing left ventricle will rebalance the myocardial blood supply/demand 
relationship. After a period of full support, it may be effective to reduce support and 
restore native pulsatility. 
Chronic studies are necessary to determine whether a transition to partial support may 
prevent myocardial atrophy and fibrosis that is seen with prolonged full support while 
still maintaining adequate end-organ blood flow. These studies should not be performed 
in normal animals. Our bovine model of chronic, ischemic heart failure is appropriate for 
such a study. 
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II. Future Directions 
Recent international experience with continuous-flow devices has progressively 
improved clinical outcomes and the quality of life of patients that receive mechanical 
circulatory support. New databanks for implantable cardiac devices such as 
INTERMACS will increase this trend. As devices are miniaturized for earlier support 
with less-invasive operative approaches, the incidence and prevalence of long-term 
mechanical circulatory support is likely to increase globally. 
Less-invasive surgical approaches and strategies oflong-term partial unloading of the 
heart must be further investigated and refined. Invasive full-support devices may still be 
reserved as a final treatment option for patients with life-threatening, end-stage heart 
failure as a bridge to heart transplantation or as a destination therapy. In contrast, less-
invasive partial-support devices may prove successful for the management of less-severe 
heart failure and relieve heart transplantation waiting lists as a destination therapy or as a 
bridge to myocardial recovery. Partial-support devices may interrupt the progressive 
hemodynamic deterioration of heart failure, improve symptoms and quality of life, 
promote reverse myocardial remodeling, and allow for device explantation in select 
patients. 
With these goals in mind, additional chronic studies on effects of full and partial support 
are needed to investigate mechanisms of pathological remodeling, reverse myocardial 
remodeling, functional myocardial recovery, and pathophysiological responses to 
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mechanical circulatory support. The mechanisms of histological changes in the 
myocardium and conduit arteries are largely unknown. Endothelial cells are affected by 
altered pulsatility and shear stress, but the role(s) of the endothelium in remodeling 
processes are unknown. Similarly, angiogenesis is dependent on pulsatility and shear 
stress and may be affected by systemic flow alterations with a continuous-flow LV AD. 
Interactions between the autonomic nervous system and flow alterations with a 
continuous-flow LV AD have not been defined but likely include altered baroreceptor 
reflex sensitivity, catecholamine release, and arterial tone. These processes, which are 
influenced by hemodynamic alterations, may affect end-organ blood flow, functional 
capacity, and potential for recovery. 
Going forward, experiments may be designed in which animals receive prolonged partial 
or full support (or a combination of the two) with a continuous-flow L V AD. In these 
studies it will be possible to further understand acute and chronic responses to 
continuous-flow mechanical circulatory support. 
Our model of chronic, ischemic heart failure is an appropriate and clinically relevant 
heart failure substrate. Chronic studies will assist to further understand basic pulsatile 
physiology as well as to define the clinical utility of partial support toward myocardial 
recovery. 
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Ultimately, proper patient selection will be critical to achieve success with any device. 
Device therapy should be tailored to patient needs. As such, careful examination of 
preclinical and clinical experiences with current and future generations of implantable 
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